

**GENERAL INFORMATION
FOR THE 2010 CDDW/ANNUAL CASL WINTER MEETING**

SCIENTIFIC SESSIONS:

The Gastroenterology Residents in Training (GRIT) Program (by invitation only) will be held at the Fairmont Royal York.

Registration Desk Hours – Mezzanine Balcony East	
Wednesday, February 24	12h00-21h30
Thursday, February 25	07h00-12h30
	16h30-20h30
Friday, February 26	07h00-19h00

The Scholars' Program (by invitation only) will be held at the Fairmont Royal York.

Registration Desk Hours – Mezzanine Balcony North	
Thursday, February 25	13h00-16h00
Friday, February 26	07h00-15h30

All core sessions of the CDDW/CASL Winter Meeting will be held at the Fairmont Royal York.

Registration Desk Hours – Canadian Room Foyer	
Friday, February 26	12h00-21h00
Saturday, February 27	06h00-17h30
Sunday, February 28	07h00-17h30
Monday, March 1	07h00-17h30
Tuesday, March 2	07h00-12h00

EXHIBIT HOURS

The Exhibit and Trade Show will be held in the Canadian Room and Foyer at the Fairmont Royal York, and will be open to all during the following hours:

Saturday, February 27	10h00-18h30
Sunday, February 28	10h00-16h00
Monday, March 1	10h00-16h00

SLIDE PREVIEW ROOM

Please note that all speakers are asked to present themselves at the Slide Preview Room, the Prince Edward Island Room, at least two hours before their presentation.

Slide Preview Room Hours

Friday, February 26	17h00-21h00
Saturday, February 27	07h00-18h00
Sunday, February 28	07h00-18h00
Monday, March 1	07h00-18h00
Tuesday, March 2	07h00-09h00

NOTE: Absolutely NO presentation preparation/loading will be permitted to take place in the Concert Hall or any session room.

GALA – Variety is the Spice of Life!

This year's Gala offers an exciting evening of diverse cultural entertainment, a great meal and of course, fun. Unique entertainers spice up the event and a variety of interactive surprises are sure to please. Join us on Monday, March 1, 2010 at 19h30 for an enjoyable evening where the focus is on terrific cuisine, a convivial atmosphere and a sparkling roster of performance artists! Tickets are \$100 and are available at the Registration Desk.

ACCREDITATION

The CDDW/CASL Winter Meeting has been accredited as a group learning activity (section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada (as the conference overall includes at least 25% interactive time). See page 33 for a listing of credits per session. Financial support for sponsored sessions, as indicated within the program, is through unrestricted educational grants.

Through an agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada the Canadian Association of Gastroenterology (CAG) designated this live educational activity 2010 CDDW/CASL Winter Meeting for a maximum of 25.5 AMA PRA category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

The 2010 CDDW/CASL Winter Meeting is endorsed by:



Faculty who are ACG Fellows or Masters are identified through the program by the † symbol

**CDDW – CASL WINTER MEETING
IMPLEMENTATION COMMITTEE**

Co-Chairs
Dave Morgan, *CAG President Elect*
Winnie Wong, *CASL President Elect*

CAG Committee
Alaa Rostom, *Education*
Stephen Vanner, *Research*
Derek McKay, *Finance*
Paul Sinclair, *Executive Director*

CASL Committee
Eric Yoshida, *President*
Rob Myers, *Education*
Andrew Mason, *Research*
Robert Bailey, *Finance*

GRIT Course
Gary May, Dana Farina, Steve Martin

Scholars' Program
Jamie Gregor, Clarence Wong, Phil Wong

**The CAG & CASL gratefully acknowledge the following
companies for their financial support towards the
2010 CDDW & Annual CASL Winter Meeting**

Gold Sponsors
Abbott Canada
Merck & Co., Inc.
Olympus Canada
UCB Pharma Canada
Nycomed Canada
Fairmont Royal York

Silver Sponsors
AstraZeneca Canada
Axcan Pharma
Pentax Canada
Takeda Canada

Bronze Sponsors
Ferring Pharmaceuticals
Gilead Sciences

**The CAG gratefully recognizes our Corporate
Sponsors**

Benefactors
AstraZeneca Canada Inc.
Abbott Canada
Merck & Co., Inc.
Olympus Canada Inc.
UCB Pharma Canada Inc.
Axcan Pharma Inc.
Pentax Canada Inc.

Partners
Nycomed Canada Inc.
Ferring Pharmaceuticals
Takeda Canada, Inc.
Baxter Corporation

Supporters
Shire Canada Inc.
AMT

**GASTROENTEROLOGY RESIDENTS IN TRAINING (GRIT)
PROGRAM AT A GLANCE**

	Wednesday, February 24	Thursday, February 25	Friday, February 26	
<i>AM</i>		Breakfast & Small Groups	Breakfast & Small Groups	
		Case Discussion	Case Discussion	
		Poster Session I cont'd & Coffee	Poster Session II cont'd & Coffee	
<i>MID-DAY</i>		Plenary Session I	Plenary Session III	
		Lunch	Lunch	
<i>PM</i>		Ivan T Beck Lectureship		Plenary Session IV
		CAG Young Educator Award Lecture		McKenna Lecturer
		Statistics Symposium	Plenary Session II	Gastroenterology Jeopardy
		Dinner	Dinner	Dinner
		Debate	Endoscopy Video Forum	Awards, Evaluation, Close
	Poster Session I	Poster Session II		

All sessions of the GRIT Program will be held at the Fairmont Royal York.

Session Learning Objectives: The program is designed to foster communication between trainees in gastroenterology and hepatology, promote research for the residents, develop presentation skills, and deliver new knowledge in key areas related to the science and practice of gastroenterology and hepatology.

Sponsored by Axcan and the Fairmont Royal York

GRIT PROGRAM

WEDNESDAY, FEBRUARY 24

Mezzanine Balcony East
12h00-15h45 Registration

Tudor 7 and 8
15h45 Opening Remarks – Gary May

16h00 Ivan T Beck Lectureship: 'Advancing the Endoscopic Limits: ESD or EMR for the Management of Esophageal Dysplasia and Early Cancer'
– Norm Marcon

16h45 CAG Young Educator Award: 'Presentation Skills – How to Give a Talk They Will Remember'
– Kelly Burak

17h30 Symposium: 'Primer in Statistics'
17:30 Statistics Primer I – Robert Hilsden
18:00 Statistics Primer II – Alaa Rostom
18:30 Q&A

Library
18h45 Dinner

Tudor 7 and 8
19h45 Debate: 'Living Anonymous Donor Transplant is Ethically Justified'
For – Ian McGilvray
Against – Marie Laryea

Confederation 5 and 6
20h30 Poster Session I

THURSDAY, FEBRUARY 25

08h00 Breakfast – Break Out Rooms
Case I: Liver Case (Rooms)
• Group 1: (New Brunswick) Louis Liu
• Group 2: (Nova Scotia) Dana Farina
• Group 3: (Prince Edward Island) Alaa Rostom
• Group 4: (Saskatchewan) Janice Barkey
• Group 5: (Confederation 3) Marie Laryea
• Group 6: (York) Robert Hilsden

Tudor 7 and 8
09h00 Case Presentation and Discussion
– Kelly Burak & Steve Martin

10h00 Coffee and Poster Session I continued

11h00 Plenary Session I – Liver

Territories
12h30 Lunch / Free Time

THURSDAY, FEBRUARY 25 (Continued)

Tudor 7 and 8
16h30 Plenary Session II – IBD and Inflammation

Territories
18h00 Dinner

Tudor 7 and 8
19h30 Endoscopy Video Forum – Gary May

Confederation 5 and 6
21h00 Poster Session II

FRIDAY, FEBRUARY 26

08h00 Breakfast – Break Out Rooms
Case II: Luminal Case (Rooms)
• Group 1: (New Brunswick) Dana Farina
• Group 2: (Nova Scotia) Alaa Rostom
• Group 3: (Prince Edward Island) Steve Martin
• Group 4: (Library) Janice Barkey
• Group 5: (Algonquin) Marie Laryea
• Group 6: (York) Joe Romagnuolo

Tudor 7 and 8
09h00 Case Presentation and Discussion
– Louis Lou and Robert Hilsden

10h00 Coffee and Poster Session II continued

11h00 Plenary Session III – Endoscopy

Territories
12h30 Lunch / Free Time

Tudor 7 and 8
14h00 Plenary Session IV – Clinical Practice

15h30 McKenna Lecturer: 'Opportunism as the Basis for a Career in Clinical Research'
– Eamonn Quigley, University College Cork

16h15 Gastroenterology Jeopardy
– Dana Farina and Gary May

Territories
17h00 Dinner

Tudor 7 and 8
18h00 Awards / Evaluation / Closing Remarks
– Gary May, Dana Farina and Janice Barkey

18h30 Adjourn / Evening Out

Sponsored by Axcan and the Fairmont Royal York

SCHOLARS' PROGRAM AT A GLANCE

	Thursday, February 25	Friday, February 26
<i>AM</i>		Continental Breakfast
		Opening Remarks What's Cool in Hepatology Therapeutic Endoscopy Advances in Inflammatory Bowel Disease (IBD) Panel Discussion
		Transition from Resident to Consultant
		Coffee Break and Endoscopy Challenge
<i>MID-DAY</i>	Registration	Regional Issues Women's Issues Pediatrics
		Buffet Lunch
<i>PM</i>	Opening Remarks & Introductions Getting into a Gastroenterology Fellowship Program Being a Gastroenterology Fellow Panel Discussion	Life of a Gastroenterologist in Research Life of a Community Gastroenterologist Life of a Gastroenterologist in Medical Education Life of a Pediatric Gastroenterologist Advances in Gastrointestinal Imaging Panel Discussion
	Prepare an Effective Presentation / Be an Effective Speaker Critical Appraisal Skills Ethical Issues Panel Discussion	Group Presentations Closing Remarks & Completion of Evaluations
	Landmark Papers in Gastroenterology	
	Buffet Dinner and Work on Group Assignments	Bus Departure to Restaurant
		Life of a Gastroenterologist in the U.S. vs. Canada Dinner

All sessions of the Scholars' Program will be held at the Fairmont Royal York.

Program Learning Objectives: The Scholars' Program is structured to identify exceptional medical students and PGY 1 and PGY 2 Internal Medicine and Pediatric Residents and to encourage them to consider a career in gastroenterology / hepatology.

The program will educate the student/resident in the attributes required to enjoy a successful career in medicine, gastroenterology / hepatology and pediatrics. The candidate will have the opportunity to work with and learn from an internationally recognized academic and clinical faculty who are respected leaders and role models in the field.

Sponsored by Nycomed

SCHOLARS' PROGRAM

THURSDAY, FEBRUARY 25			
		09h05	Therapeutic Endoscopy – Gary May
Day 1:	Welcome / Orientation and Planning a Career in Gastroenterology / Hepatology	09h35	Advances in IBD – Mark Silverberg
	Mezzanine Balcony North 13h00-16h00 Registration	10h05	Panel Discussion – Clinical Care
	Confederation 3	10h20	The Transition from Resident to Consultant: Pleasures and Pitfalls – Nilesh Chande
16h00	Opening Remarks, Faculty and Student/Resident Introductions – Jamie Gregor, Program Co-Chair	10h50	Coffee Break and Endoscopy Challenge (10h50 – 12h00) - Nilesh Chande
16h30	What Does It Take to Get into a Gastroenterology Fellowship Program? – Clarence Wong, Program Co-Chair	11h00	Regional Issues - Phil Wong / Clarence Wong / Mark Borgaonkar
17h00	What Is It Like To Be a Gastroenterology Fellow? / What Are We (and programs) Looking for? - Khurram Khan	11h20	Women's Issues - Mary Anne Cooper/Connie Switzer
17h30	Panel Discussion – Gastroenterology Training	11h40	Pediatrics - Steve Martin / Jamie Gregor
17h50	How to Prepare an Effective Presentation and Be an Effective Speaker – Clarence Wong	12h00	Buffet Lunch
18h20	Critical Appraisal Skills – Mark Borgaonkar	13h00	The Life of a Gastroenterologist in Research – Mark Silverberg
18h40	Ethical Issues - Cliff Ottaway	13h30	The Life of the Community Gastroenterologist – Connie Switzer
19h00	Panel Discussion – Presentation Skills	14h00	The Life of a Gastroenterologist in Medical Education – Mary Anne Cooper, CAG Education Committee Representative
19h20	Landmark Papers in Gastroenterology – Phil Wong, CASL Representative	14h30	The Life of a Pediatric Gastroenterologist – Steve Martin
	Algonquin	15h00	Advances in Gastrointestinal Imaging – Joe Romagnuolo
19h40	Buffet Dinner	15h30	Panel Discussion – Career Choices
	Confederation 3	15h50	Nutrition Break
20h40	Work on Group Assignments	16h10	Group Presentations
22h30	Adjournment	17h30	Closing Remarks and Completion of Evaluations – Jamie Gregor ***
		18h30	Bus Departure to Off-site Dinner and Presentation
	Confederation 3	19h30	The Life of a Gastroenterologist in the U.S. vs. Canada – Joe Romagnuolo
07h30	Continental Breakfast	20h00	Dinner
	Confederation 3		***
08h30	Opening Remarks – Clarence Wong		
08h35	What's Cool in Hepatology – Phil Wong		

FRIDAY, FEBRUARY 26

Day 2: Clinical Advances in Gastroenterology /
Hepatology and Lifestyles of a
Gastroenterologist/Hepatologist

Confederation 3
07h30 Continental Breakfast

Confederation 3
08h30 Opening Remarks
– Clarence Wong

08h35 What's Cool in Hepatology
– Phil Wong

Sponsored by Nycomed

CDDW/CASL WINTER MEETING – PROGRAM AT A GLANCE

Start	SATURDAY February 27		SUNDAY February 28				MONDAY March 1				TUESDAY March 2		Start
07h00 ▼	Registration		CAG Annual General Meeting				CASL Annual General Meeting						07h00 ▼
07h30 ▼			07h30 ▼										
08h00 ▼			08h00 ▼										
08h30 ▼	Postgraduate Course: Debating the Hot Issues in Colorectal Cancer Screening		CAG Symposium: Danger Signaling and Host Defense	Breakfast: Difficult IBD	Breakfast: Cholestatic Liver Disease	Breakfast: Celiac Disease Challenges	CASL Symposium: Liver Transplant	Breakfast: Difficult IBD	Breakfast: Approach to Liver Masses	Breakfast: Upper GI Bleeding	CAG/CASL Symposium: Recent Key Papers for Clinicians		08h30 ▼
09h00 ▼				CLF-CASL Sass Kortsak Lecture				Young Investigator Award Lecture					09h00 ▼
09h30 ▼				CLF-CASL Gold Medal Lecture				Research Excellence Award Lecture					09h30 ▼
10h00 ▼								Education Excellence Award Lecture					10h00 ▼
10h30 ▼				Nutrition Break		Nutrition Break				Nutrition Break			Nutrition Break
11h00 ▼	CASL Basic Paper Session	Postgraduate Course: Debating Hot Issues in Colorectal Cancer Screening	Workshop for Trainees	Small Group Sessions			CASL Basic Paper Session	CAG Basic Paper Session	Small Group Sessions		Liver Small Group	Luminal Small Group	11h00 ▼
11h30 ▼				Small Group Sessions		Small Group Sessions			11h30 ▼				
12h00 ▼				Small Group Sessions		Small Group Sessions			12h00 ▼				
12h30 ▼	Lunch		Lunch				Lunch				12h30 ▼		
13h00 ▼	Lunch		Lunch				Lunch				13h00 ▼		
13h30 ▼	CAG Clinical Paper Session	Postgraduate Course: The Liver & Other Organs	CAG Basic Paper Session	CASL Clinical Paper Session	CAG Symposium: Advances in IBD Diagnosis and Therapeutics		CASL Symposium: Update in HBV	CAG Basic Paper Session	Live Endoscopy 1				13h30 ▼
14h00 ▼													14h00 ▼
14h30 ▼													14h30 ▼
15h00 ▼	Nutrition Break		Nutrition Break				Nutrition Break				15h00 ▼		
15h30 ▼	CAG Symposium: New Insights into Neuro- gastroenterology	Postgraduate Course: Metabolic Liver Disease	Poster Session 1				CASL Symposium: 'Omics' in Liver Disease	CAG Symposium: Biomarkers in GI Malignancies	Live Endoscopy 2 (15h05-16h45)				15h30 ▼
16h00 ▼													16h00 ▼
16h30 ▼							16h30 ▼						
17h00 ▼							Poster Session 2		17h00 ▼				
17h30 ▼							Poster Session 2		17h30 ▼				
18h00 ▼	McKenna Reception										18h00 ▼		
18h30 ▼	McKenna Lecture		Evening Event: Research in Canada - Strategic Directions from our Funding Partners	Evening Event: Dealing with Anticoagulants	Evening Event: Future of Hepatitis C Therapy - Peginterferon, Ribavirin, and Beyond	Evening Event: Screening Colonoscopy - How Do We Make a Difference?	CAG/CASL Awards Ceremony				18h30 ▼		
19h00 ▼							CAG/CASL Awards Ceremony		19h00 ▼				
19h30 ▼							CAG/CASL Awards Ceremony		19h30 ▼				
20h00 ▼							Gala Evening				20h00 ▼		

GI gastrointestinal; HBV hepatitis B virus; IBD inflammatory bowel disease;

SATURDAY FEBRUARY 27

CAG/CASL POSTGRADUATE COURSE

Learning Objectives: Specialists may be defined by their knowledge of the leading edge issues in gastroenterology and hepatology. The objectives of the course are to bring you up to date on developments in selected areas and get you ready for the challenges of 2010. Experts will present their approaches to common, and some uncommon, clinical issues with an emphasis on what's new, not a comprehensive review. We will mine the recent literature in colorectal cancer screening, the impact of liver disease on other organs and systems, and metabolic liver disease, and present the information you really need to know.

08h30-10h30	<p>CAG/CPAC/CASL POSTGRADUATE COURSE Debating the Hot Issues in Colorectal Cancer Screening – Part 1</p> <p>Co-Chairs: Heather Bryant, Canadian Partnership against Cancer (CPAC) and Des Leddin, Dalhousie University</p> <ul style="list-style-type: none">• Current Status and Components of a Provincial Screening Program – What Have We Learned? Heather Bryant• Population Screening Tools – Options and Effectiveness Robert Hilsden, University of Calgary• Serrated Polyps, Adenomas and Right-Sided Lesions Harjinder Singh, University of Manitoba• Current Screening Guidelines in the US and Canada – Similarities and Differences Des Leddin• Ensuring and Measuring Quality in a Screening Program David Armstrong†, McMaster University• Question and Answer	Concert Hall
10h00-16h00	<p>ASGE LEARNING CENTRE (See page 26)</p> <p>– Afternoon sponsored by Ferring –</p>	Canadian
10h30-11h00	Exhibits and Nutrition Break	Canadian Room & Foyers
11h00-12h30	<p>CAG/CPAC/CASL POSTGRADUATE COURSE Debating the Hot Issues in Colorectal Cancer Screening – Part 2</p> <p>Co-Chairs: Heather Bryant, CPAC and Des Leddin, Dalhousie University</p> <ul style="list-style-type: none">• DEBATE: <i>'Population screening should be based on cancer prevention – not cancer detection'</i> Pro: Donald MacIntosh, Dalhousie University Con: Linda Rabeneck†, University of Toronto• Panel Discussion (all speakers)• Question and Answer	Concert Hall
11h00-12h30	<p>CASL BASIC PAPER SESSION</p> <p>Co-Chairs: Thomas Michalak, Memorial University and Claudia Zwingmann, Université de Montréal</p> <ul style="list-style-type: none">• Spontaneous clearance and viral dynamics during recent hepatitis C virus infection (Abstract 1) – J Grebely¹, K Petoumenos¹, M Hellard², G Matthews¹, P Marks¹, P Haber³, W Rawlinson⁴, A Lloyd⁵, P White⁵, J Kaldor¹, G Dore¹ <i>¹National Centre in HIV Epidemiology & Clinical Research and ⁵School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia; ²Burnet Institute, Melbourne, VIC, Australia; ³University of Sydney and ⁴Prince of Wales Hospital, Sydney, NSW, Australia</i>	Ontario

SATURDAY FEBRUARY 27

CASL Student Prize

- Comparison of immune restoration in early versus late interferon alpha therapy against hepatitis C virus (Abstract 2)
 - M Abdel-Hakeem¹, N Bédard¹, G Badr¹, M Ostrowski⁴, J Bruneau³, R Sékaly¹, B Willems², J Heathcote⁵, N Shoukry¹
¹Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Hôpital St-Luc, Montréal, Québec; ²Département de médecine et ³Département de médecine familiale, Université de Montréal, Montréal, Québec; ⁴Department of Immunology, University of Toronto, Toronto, Ontario; ⁵Toronto Western Hospital, Toronto, Ontario
- Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection (Abstract 3)
 - L Chen, I Borozan, J Sun, M Guindi, S Fischer, J Feld, N Anand, J Heathcote, A Edwards, I McGilvray
University of Toronto, Toronto, Ontario
- Inhibition of CD4+ T lymphocyte proliferative response following ex vivo exposure to wild-type hepatitis C virus (Abstract 4)
 - S MacParland, T Pham, T Michalak
Molecular Virology and Hepatology Research Group, Faculty of Medicine, Memorial University, St. John's, Newfoundland
- Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection (Abstract 5)
 - L Zhao, D Tyrrell
University of Alberta, Edmonton, Alberta

CASL Student Prize

- CD5 as a molecule mediating entry of hepatitis C virus to human T lymphocytes (Abstract 6)
 - M Sarhan, T Michalak
Memorial University, St. John's, Newfoundland

12h30-13h15

Exhibits and Lunch

Canadian Room & Foyers

13h15-14h45

CAG CLINICAL PAPER SESSION

Ontario

Co-Chairs: Nicola Jones, University of Toronto and John Marshall, McMaster University

- Epidemiological risk factors for childhood onset inflammatory bowel disease in Scotland: A case-control study (Abstract 7)
 - J Van Limbergen¹, H Spiers², R Farhadi², M Wilson², H Drummond², P Henderson², R Russell², J Satsangi², D Wilson²
¹Sick Kids Hospital, Toronto, Ontario; ²Scottish Paediatric Gastroenterology, Hepatology & Nutrition Group, Edinburgh, United Kingdom
- Low income children with inflammatory bowel disease have higher surgical and hospitalization rates in a universal health care system: Results from the Ontario Crohn's and Colitis cohort (Abstract 8)
 - E Benchimol¹, T To¹, A Griffiths¹, L Rabeneck², A Guttman²
¹The Hospital for Sick Children, Toronto, Ontario; ²The Institute for Clinical Evaluative Sciences, Toronto, Ontario
- Validity of administrative data in identifying in-hospital complications in ulcerative colitis patients undergoing colectomy (Abstract 9)
 - M Crespín¹, C Ma², M Proulx², S DeSilva², M Pruscinkewicz², C Seow², R Panaccione², S Ghosh², J Hubbard², R Myers², G Kaplan²
¹University of Alberta, Edmonton, Alberta; ²University of Calgary, Calgary, Alberta
- Poor stage IIB survival in a population-based cohort of colorectal cancer patients (Abstract 10)
 - R Urquhart¹, G Porter², J Bu¹, R Dewar¹, E Grunfeld³
¹Cancer Care Nova Scotia, Halifax, Nova Scotia; ²Department of Surgery, Dalhousie University, Halifax, Nova Scotia; ³Ontario Institute for Cancer Research and Dept of Family and Community Medicine, University of Toronto, Toronto, Ontario
- Mild CFTR mutations are associated with risk of pancreatitis (Abstract 11)
 - C Ooi¹, K Keenan¹, R Dorfman¹, T Gonska¹, N Anderson¹, M Cipolli², C Castellani², P Durie¹
¹SickKids, Toronto, Ontario; ²Verona CF Centre, Verona, Italy

SATURDAY FEBRUARY 27

- Outcomes of colorectal cancer screening with flexible sigmoidoscopy performed by trained nurses at a Canadian tertiary health care centre (Abstract 12)
 - L Win, T Corner, P Moayyedi, K Khan
McMaster University, Hamilton, Ontario

13h15-14h45

CAG/CASL POSTGRADUATE COURSE The Liver and Other Organs

Concert Hall

Co-Chairs: Sam Lee, University of Calgary and Jean-Pierre Villeneuve, Université de Montréal

- Liver and the Lungs: Hepatopulmonary Syndrome and Portopulmonary Hypertension
George Therapondos, University of Toronto
- Vascular Disorders of the Liver: Budd Chiari and Beyond
Puneeta Tandon, University of Alberta
- Bone Disease in Patients with Cirrhosis
Angela Cheung, University of Toronto
- Question and Answer

14h45-15h15

Exhibits and Nutrition Break

Canadian Room & Foyers

15h15-17h15

CAG/CASL POSTGRADUATE COURSE Metabolic Liver Disease

Concert Hall

Co-Chairs: Paul Adams, University of Western Ontario and Kevork Peltekian, Dalhousie University

- Chasing the Ferritin
Melanie Beaton, University of Western Ontario
- Bariatric Surgery and Weight Loss Agents for Non-alcoholic Fatty Liver Disease (NAFLD)
Margherita Cadeddu, McMaster University
- Celiac Disease and the Liver
Alaa Rostom, University of Calgary
- IgG 4 and the Hepatologist
Gideon Hirschfield, University of Toronto
- Question and Answer

15h15-17h15

CAG SYMPOSIUM New Insights in Neurogastroenterology

Ontario

Learning Objectives:

At the end of this session, participants will be able to:

1. Understand intercellular communication in the enteric nervous system in health and disease.
2. Appreciate that neurotransmitters and enteroendocrine substances can modulate inflammation.
3. Realize the therapeutic potential of cannabinoids in intestinal disorders.

Co-Chairs: Alan Lomax, Queen's University and Keith Sharkey, University of Calgary

- Inflammation-induced Remodeling of the Enteric Nervous System
Pierre-Yves Gougeon, Queen's University
- The Molecular Basis of Vagal Satiety Signaling
Donna Daly, Queen's University
- Enteric Neuro-glial Signaling
Brian Gulbransen, University of Calgary
- Emerging Roles for Enterochromaffin Cells during Intestinal Inflammation
Waliul Khan, McMaster University

SATURDAY FEBRUARY 27

- Purinergic Signaling to the Gut Immune System
Fernand-Pierre Gendron, Université de Sherbrooke
- Cannabinoid Regulation of Gut Functions: From Bench to Bedside
Martin Storr, University of Calgary

17h30-18h30

MCKENNA RECEPTION

Canadian Room & Foyers

18h30-19h30

MCKENNA LECTURE

Irritable Bowel Syndrome (IBS) 2010: Light in the Tunnel at the End of the Light?
Eamonn Quigley†, University College Cork, Ireland
– Introduction by Ron Bridges

Concert Hall

– McKenna Reception and Lecture sponsored by UCB –

SUNDAY FEBRUARY 28

07h00-08h00	CAG ANNUAL GENERAL MEETING (breakfast from 06h30)	Concert Hall
08h00-09h00	*CAG BREAKFAST WITH THE EXPERTS Difficult Cases in Inflammatory Bowel Disease (IBD)	Algonquin, British Columbia
<hr/>		
Learning Objectives: At the end of this session, participants will be able to: 1. Manage complex IBD with appropriate introduction of approved therapies. 2. Recognize patients who are candidates for biologic therapy. 3. Be familiar with the common side effect profiles of conventional non-biologic and biologic therapy.		
<hr/>		
Co-Chairs: Gil Kaplan, University of Calgary and Mark Silverberg, University of Toronto Session Leaders: Gordon Greenberg, University of Toronto; Gil Kaplan, University of Calgary; Simon Travis, John Radcliffe Hospital, Oxford, England; Hillary Steinhart, University of Toronto A Crohn's disease case will be presented in the Algonquin Room and an ulcerative colitis case will be covered in the British Columbia Room *Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts <p style="text-align: center;">– Sponsored by Merck & Co.–</p>		
08h00-09h00	*CASL BREAKFAST WITH THE EXPERTS Cholestatic Liver Diseases – An Update	Quebec, Manitoba
<hr/>		
Learning Objectives: At the end of this session, participants will be able to: 1. Evaluate and treat a patient with the 'overlap syndrome'. 2. Discuss diagnostic and therapeutic modalities for primary sclerosing cholangitis (PSC). 3. Describe the natural history of a patient with primary biliary cirrhosis (PBC).		
<hr/>		
Co-Chairs: Cameron Ghent, University of Western Ontario and Alnoor Ramji, University of British Columbia Session Leader: Gideon Hirschfield, University of Toronto *Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts		
08h00-09h00	*CAG BREAKFAST WITH THE EXPERTS Celiac Disease Challenges	Alberta, Saskatchewan
<hr/>		
Learning Objectives: At the end of this session, participants will be able to: 1. Evaluate problems and pitfalls of celiac serological testing, including the evaluation of a patient with IgA deficiency. 2. Discuss the management of patients with mildly abnormal (Marsh 1 or 2) or normal intestinal biopsies with abnormal celiac testing serology. 3. Examine the relationship between 'non-gastrointestinal autoimmune disease' and celiac disease. 4. Discuss the options for therapy in patients who have gained a symptomatic but not a complete histological response to a gluten-free diet.		
<hr/>		
Co-Chairs: Decker Butzner, University of Calgary and Jamie Gregor, University of Western Ontario Session Leaders: Collin Barker, University of British Columbia; Connie Switzer, University of Alberta *Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts		

SUNDAY FEBRUARY 28

08h30-10h30	<p>CAG SYMPOSIUM Danger Signaling and Host Defense; NODs, TLRs, NLRPs and More!</p> <hr/> <p>Learning Objectives: At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Understand how the gut responds to danger and the role of the innate immune response. 2. Be familiar with danger signals and associated pathways. 3. Develop an understanding of how these pathways may play a role in intestinal homeostasis and disease. <hr/> <p>Co-Chairs: Paul Beck, University of Calgary and Dana Philpott, University of Toronto</p> <ul style="list-style-type: none"> • Introduction Paul Beck • Nod-like Receptors (NLRs), Inflammasomes and Disease Dan Muruve, University of Calgary • Intravascular Immunity in the Liver: Responses to Bugs and Danger Paul Kubes, University of Calgary • Mechanisms that Regulate Targeting of Bacterial Pathogens to the Autophagy System of Host Cells John Brumell, University of Toronto • Interactions between Nod2 and Autophagy Pathways: A New Axis with Implications in Crohn's Disease Leo Travassos, University of Toronto • Concluding Remarks Dana Philpott, University of Toronto 	Ontario
09h00-09h45	<p>CLF-CASL SASS KORTSAK LECTURE Taking the Fe Out of Neonatal Hemochromatosis and Putting the Fc In Peter F Whittington, Northwestern University – Introduction by Eve Roberts and the Canadian Liver Foundation</p>	Concert Hall
09h45-10h30	<p>CLF-CASL GOLD MEDAL LECTURE The 'Irony' of Clinical Investigation Paul Adams, University of Western Ontario – Introduction by Eric Yoshida and the Canadian Liver Foundation</p>	Concert Hall
10h00-16h00	<p>ASGE LEARNING CENTER (See page 26) – Sponsored by Ferring Pharmaceuticals –</p>	Canadian
10h30-11h00	<p>Exhibits and Nutrition Break</p>	Canadian Room & Foyers
11h00-12h30	<p>WORKSHOP FOR TRAINEES Dispatches from the Front Lines of the Research World</p> <hr/> <p>Learning Objectives: At the end of this session, participants will:</p> <ol style="list-style-type: none"> 1. Understand the opportunities and career path for PhD students pursuing post doctoral training. 2. Understand the challenges and rewards of establishing your own laboratory. <hr/> <p>Co-Chairs: Mélanie Gareau, University of Toronto and Stephen Vanner, Queen's University</p> <ul style="list-style-type: none"> • "I Have My PhD! Now What?" Mélanie Gareau • "I Have My Own Lab! Now What?" Part 1 John Brumell, University of Toronto • "I Have My Own Lab! Now What?" Part 2 Elaine Petrof, Queen's University 	Ontario

SUNDAY FEBRUARY 28

11h00-11h40	<p>*SMALL GROUP SESSIONS (See details on pages 27-32)</p> <table border="0" style="width: 100%;"> <tr> <td style="padding: 2px 10px 2px 20px;">IBD Treatments and the Elderly</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">British Columbia</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Treatment of Eosinophilic Esophagitis across the Age Spectrum</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Quebec</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Difficult Esophageal Stricture (Sponsored by Pentax)</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Algonquin</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Polypectomy Techniques to Avoid Complications and Recurrence</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Manitoba</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Capsule/Balloon-assisted Enteroscopy/CT Enteroclysis – Diagnostic Usage</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Alberta</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Autoimmune Biliary and Pancreatic Diseases</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Saskatchewan</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Mechanisms Underlying Probiotic Actions in the Gastrointestinal (GI) Tract</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Nova Scotia</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">The Many Uses of Transjugular Intrahepatic Portosystemic Shunt (TIPS)</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">New Brunswick</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Pediatric NAFLD</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Salon A</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Management of Hepatocellular Carcinoma (HCC) (Sponsored by Gilead)</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Toronto</td> </tr> </table> <p>*Please note that pre-registration (online or on-site) is required to gain admittance to Small Group Sessions</p>	IBD Treatments and the Elderly	British Columbia	Treatment of Eosinophilic Esophagitis across the Age Spectrum	Quebec	Difficult Esophageal Stricture (Sponsored by Pentax)	Algonquin	Polypectomy Techniques to Avoid Complications and Recurrence	Manitoba	Capsule/Balloon-assisted Enteroscopy/CT Enteroclysis – Diagnostic Usage	Alberta	Autoimmune Biliary and Pancreatic Diseases	Saskatchewan	Mechanisms Underlying Probiotic Actions in the Gastrointestinal (GI) Tract	Nova Scotia	The Many Uses of Transjugular Intrahepatic Portosystemic Shunt (TIPS)	New Brunswick	Pediatric NAFLD	Salon A	Management of Hepatocellular Carcinoma (HCC) (Sponsored by Gilead)	Toronto
IBD Treatments and the Elderly	British Columbia																				
Treatment of Eosinophilic Esophagitis across the Age Spectrum	Quebec																				
Difficult Esophageal Stricture (Sponsored by Pentax)	Algonquin																				
Polypectomy Techniques to Avoid Complications and Recurrence	Manitoba																				
Capsule/Balloon-assisted Enteroscopy/CT Enteroclysis – Diagnostic Usage	Alberta																				
Autoimmune Biliary and Pancreatic Diseases	Saskatchewan																				
Mechanisms Underlying Probiotic Actions in the Gastrointestinal (GI) Tract	Nova Scotia																				
The Many Uses of Transjugular Intrahepatic Portosystemic Shunt (TIPS)	New Brunswick																				
Pediatric NAFLD	Salon A																				
Management of Hepatocellular Carcinoma (HCC) (Sponsored by Gilead)	Toronto																				
11h40-11h50	Break																				
11h50-12h30	<p>*SMALL GROUP SESSIONS (See details on pages 27-32)</p> <table border="0" style="width: 100%;"> <tr> <td style="padding: 2px 10px 2px 20px;">Non-cardiac Chest Pain</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">British Columbia</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Quebec</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Quality Assurance and Patient-centered Endoscopy Services in the Era of Limited Resources (Sponsored by Pentax)</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Algonquin</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Endoscopic vs. Surgical Management of Large or Malignant Polyps (Sponsored by Olympus)</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Manitoba</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Enteral Stenting</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Alberta</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Statistics Primer</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Saskatchewan</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Patch-Clamping for the Non-Patch Clamper</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Nova Scotia</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Management of Non-esophageal Varices</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">New Brunswick</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Portal Hypertension in Pregnancy</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Salon A</td> </tr> <tr> <td style="padding: 2px 10px 2px 20px;">Cystic Diseases of the Liver</td> <td style="text-align: right; padding: 2px 10px 2px 20px;">Toronto</td> </tr> </table> <p>*Please note that pre-registration (online or on-site) is required to gain admittance to Small Group Sessions</p>	Non-cardiac Chest Pain	British Columbia	Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics	Quebec	Quality Assurance and Patient-centered Endoscopy Services in the Era of Limited Resources (Sponsored by Pentax)	Algonquin	Endoscopic vs. Surgical Management of Large or Malignant Polyps (Sponsored by Olympus)	Manitoba	Enteral Stenting	Alberta	Statistics Primer	Saskatchewan	Patch-Clamping for the Non-Patch Clamper	Nova Scotia	Management of Non-esophageal Varices	New Brunswick	Portal Hypertension in Pregnancy	Salon A	Cystic Diseases of the Liver	Toronto
Non-cardiac Chest Pain	British Columbia																				
Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics	Quebec																				
Quality Assurance and Patient-centered Endoscopy Services in the Era of Limited Resources (Sponsored by Pentax)	Algonquin																				
Endoscopic vs. Surgical Management of Large or Malignant Polyps (Sponsored by Olympus)	Manitoba																				
Enteral Stenting	Alberta																				
Statistics Primer	Saskatchewan																				
Patch-Clamping for the Non-Patch Clamper	Nova Scotia																				
Management of Non-esophageal Varices	New Brunswick																				
Portal Hypertension in Pregnancy	Salon A																				
Cystic Diseases of the Liver	Toronto																				
12h30-13h15	Exhibits and Lunch Canadian Room & Foyers																				
13h15-14h45	<p>CAG BASIC PAPER SESSION: Cell Signaling Ontario</p> <p>Co-Chairs: Isabella Tai, University of British Columbia and Bruce Vallance, University of British Columbia</p> <ul style="list-style-type: none"> • Inhibition of GSK3 activity promotes apoptosis in pancreatic cancer cells but not in pancreatic immortalized cells (Abstract 13) <ul style="list-style-type: none"> – <u>M Boucher</u>, B Marchand, I Tremblay <i>Université de Sherbrooke, FMSS, Dépt. Médecine, Serv. de Gastroentérologie, Sherbrooke, Québec</i> • The dual-specificity phosphatase DUSP4: Key regulator of the BRaf/ERK pathway during colorectal tumorigenesis (Abstract 14) <ul style="list-style-type: none"> – <u>S Cagnol</u>, E Lemieux, N Rivard <i>University of Medicine and Health Sciences, Sherbrooke, Québec</i> <p>CAG Student Prize</p> <ul style="list-style-type: none"> • Loss of HNF4α increases oxydative stress and inhibits neoplasia in the gut (Abstract 15) <ul style="list-style-type: none"> – <u>M Darsigny</u>¹, J Babeu¹, Lévy², E Seidman², F Gendron¹, J Carrier¹, N Perreault¹, F Boudreau¹ <i>¹Université de Sherbrooke, Sherbrooke, Québec; ²Université de Montréal, Montréal, Québec</i> 																				

SUNDAY FEBRUARY 28

- Regulation of rhythmic calcium oscillations underlying gut pacemaker activity (Abstract 16)
 - B Lowie
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario
- Constitutive activation of MEK/ERK pathway negatively regulates intestinal epithelial cell differentiation by inhibiting Cdx2/3 activity (Abstract 17)
 - E Lemieux, S. Mongrain, F. Boudreau, R. Nathalie
Université de Sherbrooke, Sherbrooke, Québec
- Myeloid-derived suppressor cell accumulation in the colon is associated with neoplastic changes in the interleukin-10-deficient mouse model of colitis-associated-cancer (Abstract 18)
 - M Bawa¹, R Zhang², D McCafferty¹
¹University of Calgary, Calgary, Alberta; ²Shanxi Medical University, Taiyuan, China

13h15-14h45

CASL CLINICAL PAPER SESSION

Confederation 5 and 6

Co-Chairs: Alex Aspinall, University of Calgary and Richard Schreiber, University of British Columbia

- Increased mortality on the liver transplant waiting list in females under the MELD allocation system may be eliminated by considering estimated glomerular filtration rate (Abstract 19)
 - K Burak, A Shaheen, A Aspinall, R Myers
University of Calgary Liver Unit, Calgary, Alberta
- Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative and positive patients with chronic hepatitis B (Abstract 20)
 - S Lee⁵, J Heathcote², K Kaita³, R Myers¹, M Sherman⁴, F Anderson⁵, P Marcellin⁶, J Sorbel⁷, J Anderson⁷, E Mondou⁷, F Rousseau⁷
¹Heritage Medical Research Clinic, University of Calgary, Calgary, Alberta; ²University of Toronto, Toronto, Ontario; ³John Buhler Research Centre, University of Manitoba Health Science Center, Winnipeg, Manitoba; ⁴Toronto General Hospital, Toronto, Ontario; ⁵Liver and Intestinal Research Centre, Vancouver, British Columbia; ⁶Hôpital Beaujon, Clichy, France; ⁷Gilead Sciences, Durham, North Carolina
- Significant liver fibrosis can be found among hepatitis B patients with minimally elevated ALT (Abstract 21)
 - A Alallam¹, S Fung²
¹University of Toronto, Toronto, Ontario; ²Toronto General Hospital, Toronto, Ontario
- The utility of Xenon-133 liver scan in the diagnosis and management of non-alcoholic fatty liver disease (Abstract 22)
 - S Al-Busafi, P Ghali, P Wong, M Deschênes
McGill University, Montréal, Québec
- Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation (Abstract 23)
 - A Montano-Loza, V Bain, M Ma, A Mason
Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, Alberta
- Association of liver cirrhosis with venous thromboembolism among hospitalized patients: A nationwide U.S. study (Abstract 24)
 - H Wu, G Nguyen
University of Toronto - Department of Gastroenterology, Toronto, Ontario

13h15-14h45

CAG SYMPOSIUM

Concert Hall

Advances in IBD Diagnosis and Therapeutics

Learning Objectives:

At the end of this session, participants will be able to:

1. Understand the benefits and risks of using combination immunosuppressant and anti-tumour necrosis factor (TNF) therapy in the treatment of Crohn's disease.
2. Be familiar with novel therapeutic agents other than the anti-TNF agents.
3. Be familiar with the evidence in favour of or against stopping anti-TNF therapy in Crohn's disease.

Co-Chairs: Charles Bernstein†, University of Manitoba and Alain Bitton, McGill University

SUNDAY FEBRUARY 28

- Combination Immunosuppressants and Anti-TNF Agents: Do the Benefits Outweigh the Risks?
Subrata Ghosh, University of Calgary
- Emerging Medical Therapies in IBD
Richard Fedorak, University of Alberta
- Stopping Biologics
Simon Travis, John Radcliffe Hospital, Oxford, England

– Sponsored by Abbott –

14h45-15h15 Exhibits and Nutrition Break Canadian Room & Foyers

15h15-18h00 POSTER SESSION 1 Ballroom & Salon B

Join authors and colleagues and participate in relaxed and informative sessions while enjoying beverages and light snacks. Please be sure to visit the Posters of Distinction located throughout the Exhibit Hall (Canadian Room) and Foyers.

– Sponsored by AstraZeneca –

18h00-21h00 *EVENING EVENT Alberta
Dealing with Anti-Coagulants

Learning Objectives:

At the end of this program, participants should be able to:

1. Assess an individual's risk of recurrent thromboembolism when anticoagulation is withdrawn because of gastrointestinal bleeding or anticipated therapy.
2. Initiate procedural or medical strategies to ameliorate that risk.

Faculty: Jamie Gregor, University of Western Ontario and Michael Kovacs, University of Western Ontario

*Please note that pre-registration (online or on-site) is required to gain admittance to Evening Events

– Co-developed with Nycomed –

18h00-21h00 *EVENING EVENT Quebec
The Future of Hepatitis C Therapy – Peginterferon, Ribavirin, and Beyond

Learning Objectives:

At the end of this program, participants should:

1. Understand the clinical implications of hepatitis C virus (HCV).
2. Understand the current paradigm of HCV treatment.
3. Have an awareness of HCV antiviral agents that are currently in clinical trials.

Faculty: Steve Wong, University of Manitoba and Eric Yoshida, University of British Columbia

*Please note that pre-registration (online or on-site) is required to gain admittance to Evening Events

– Co-developed with Merck & Co –

18h00-21h00 *EVENING EVENT British Columbia
Screening Colonoscopy – How Do We Make a Difference?

Learning Objectives:

At the end of this program, participants should be able to:

1. Review the key factors involved in 'quality' optical colonoscopy.
2. Ensure understanding of options available for incomplete colonoscopies.
3. Review latest CAG guidelines for colon cancer screening.
4. Ensure understanding of appropriate intervals for surveillance colonoscopy.

Faculty: Rob Enns, University of British Columbia and Ron Bridges, University of Calgary

*Please note that pre-registration (online or on-site) is required to gain admittance to Evening Events

– Co-developed with Olympus –

18h00-21h00

*EVENING EVENT

Manitoba

Research in Canada: Strategic Directions from our Funding Partners – CCFC, CDHF, CIHR & CLF

Learning Objectives:

At the end of this program, participants should:

1. Understand the strategic direction of GI research funding bodies in Canada.
 2. Be aware of available funding opportunities for GI research.
 3. Better understand the funding organizations and their research contacts.
-

Co-Chairs: Stephen Vanner, Queen's University and Richard Schreiber, University of British Columbia

Faculty:

- George Tolomiczenko, Crohn's and Colitis Foundation of Canada (CCFC)
- Richard Fedorak, Canadian Digestive Health Foundation (CDHF)
- Phil Sherman, Canadian Institutes of Health Research (CIHR)
- Kevork Peltikian, Canadian Liver Foundation (CLF)

*Please note that pre-registration (online or on-site) is required to gain admittance to Evening Events

– Sponsored by CCFC, CIHR, CAG and CASL –

MONDAY MARCH 1

07h00-08h00	CASL ANNUAL GENERAL MEETING	Ontario
08h00-09h00	*CAG BREAKFAST WITH THE EXPERTS Difficult Cases in IBD	Algonquin, British Columbia
<hr/>		
<p>Learning Objectives: At the end of this session, participants will be able to:</p> <ol style="list-style-type: none">1. Manage complex IBD with appropriate introduction of approved therapies.2. Recognize patients who are candidates for biologic therapy.3. Be familiar with the common side effect profiles of conventional non-biologic and biologic therapy.		
<hr/>		
<p>Co-Chairs: Gil Kaplan, University of Calgary and Mark Silverberg, University of Toronto</p> <p>Session Leaders: Gordon Greenberg, University of Toronto; Gil Kaplan, University of Calgary; Simon Travis, John Radcliffe Hospital, Oxford, England; Hillary Steinhart, University of Toronto</p> <p>A Crohn's disease case will be presented in the Algonquin Room and an ulcerative colitis case will be covered in the British Columbia Room</p> <p>*Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts. This is a repeat of the Saturday session.</p> <p style="text-align: center;">– Sponsored by Merck & Co –</p>		
08h00-09h00	*CASL BREAKFAST WITH THE EXPERTS Approach to Liver Masses	Quebec, Manitoba
<hr/>		
<p>Learning Objectives: At the end of this session, participants will be able to:</p> <ol style="list-style-type: none">1. Outline the approach to the diagnosis of HCC in a cirrhotic liver including the role of imaging, biopsy and AFP.2. Review the curative options for HCC and how to choose between surgery, transplant and percutaneous ablative therapies.3. Examine the role of sorafenib in the management of HCC.		
<hr/>		
<p>Co-Chairs: Kelly Burak, University of Calgary and Paul Marotta, University of Western Ontario</p> <p>Session Leaders: Natasha Chandok, University of Western Ontario; Alex Aspinall, University of Calgary</p> <p>*Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts</p>		
08h00-09h00	*CAG BREAKFAST WITH THE EXPERTS Management of Upper GI Bleeding: What Do the New Guidelines Tell Us?	Alberta, Saskatchewan
<hr/>		
<p>Learning Objectives: At the end of this session, participants will be able to:</p> <ol style="list-style-type: none">1. Understand the justification for appropriate initial resuscitation and risk stratification in the management of patients with non-variceal upper GI bleeding.2. Appreciate, as medical experts and scholars, the evidence-based roles of endoscopic and pharmacological therapies in the management of patients with non-variceal upper GI bleeding.3. Be familiar, as professionals and managers, with knowledge translation issues as they apply to the dissemination of guidelines in the management of patients with non-variceal upper GI bleeding.		
<hr/>		
<p>Co-Chairs: Alan Barkun†, McGill University and John Marshall, McMaster University</p> <p>Session Leaders: Gary May, University of Toronto; Alaa Rostom, University of Calgary; Laura Targownik, University of Manitoba; Frances Tse, McMaster University</p> <p>*Please note that pre-registration (online or on-site) is required to gain admittance to Breakfast with the Experts</p>		

MONDAY MARCH 1

09h00-10h30	CASL SYMPOSIUM Liver Transplantation	Concert Hall
	<hr/> <p>Learning Objectives: At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Understand results of liver transplantation in 2010 and its applications. 2. Know where new anti-rejection drugs fit in our armamentarium. 3. Understand new applications for liver transplantation in Canada – when applicable and where it's available. 4. Understand new developments in pediatric liver transplantation. <hr/> <p>Co-Chairs: Marc Deschênes, McGill University and Les Lilly, University of Toronto</p> <ul style="list-style-type: none"> • Update in Liver Transplantation in 2010 – Paul Marotta, University of Western Ontario • New Developments on the Canadian Liver Transplant Scene - Transplantation in HIV, cholangiocarcinoma, hepatoma, hepatitis B virus (HBV), MELD – Kevork Peltekian, Dalhousie University • Update in Pediatric Liver Transplantation – Vicky Ng, University of Toronto • Question and Answer 	
09h00-09h30	CAG YOUNG INVESTIGATOR AWARD LECTURE Reducing the Impact of IBD on Human Health: A Journey from Genes to People Mark Silverberg, University of Toronto – Introduction by Hillary Steinhart	Ontario
09h30-10h00	CAG RESEARCH EXCELLENCE AWARD LECTURE Molecular Mechanism of Pathologic Exocytosis Underlying Alcoholic Pancreatitis Herbert Gaisano, University of Toronto – Introduction by Phil Sherman	Ontario
10h00-10h30	CAG EDUCATION EXCELLENCE AWARD LECTURE Live Video Courses – More than Just a Show! Norm Marcon, University of Toronto – Introduction by Alaa Rostom	Ontario
10h00-16h00	ASGE LEARNING CENTER (See page 26)	Canadian
10h30-11h00	Exhibits and Nutrition Break	Canadian Room & Foyers
11h00-12h30	CASL BASIC PAPER SESSION Co-Chairs: Thomas Michalak, Memorial University and Julia Rempel, University of Manitoba	Ontario
	<ul style="list-style-type: none"> • Pre-treatment inducible cytokine synthesis corresponds to treatment outcomes for chronic hepatitis C virus infection (Abstract 25) – <u>J Rempel</u>, C Krueger, S Wong <i>University of Manitoba, Winnipeg, Manitoba</i> • Circulatory dysfunction after large volume paracentesis in patients with cirrhosis and ascites (Abstract 26) – <u>P James</u>, L Oosterveld, F Wong <i>University of Toronto, Toronto, Ontario</i> 	

MONDAY MARCH 1

- AST-120 (spherical carbon adsorbent) treatment prevents hyperammonemia and brain edema in cirrhotic rats (Abstract 27)
 - C Bosoi, C Parent-Robitaille, M Tremblay, C Rose
Neuroscience Research Unit, Hôpital Saint-Luc, Université de Montréal, Montréal, Québec
- Intravital visualization of the host immune response to a viral analogue in the mouse liver (Abstract 28)
 - C Jenne, P Kubes
University of Calgary, Calgary, Alberta
- Does cyclosporine protect against recurrence of primary biliary cirrhosis following liver transplantation by inhibiting betaretrovirus replication? (Abstract 29)
 - A Montano-Loza, J Bintner, W Shawn, A Mason
University of Alberta, Edmonton, Alberta
- Endogenous cytokine activity in interferon treatment induced depression (Abstract 30)
 - J Rempel, C Krueger, S Wong
University of Manitoba, Winnipeg, Manitoba

11h00-12h30

CAG BASIC PAPER SESSION: Host-microbe Interactions

Concert Hall

Co-Chairs: Alan Lomax, Queen's University and Elena Verdu, McMaster University

CAG Student Prize

- Depression induced changes in the GI tract of adult mice (Abstract 31)
 - A Park, B Patricia, M Geuking, E Verdu, P Bercik, C Stephen
McMaster University, Hamilton, Ontario
- *Lactobacillus rhamnosus* GG attenuates pro-inflammatory cytokine-induced barrier dysfunction and inflammation (Abstract 32)
 - K Donato¹, J Wang¹, P Sherman²
¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario; ²Program in Cell Biology, Research Institute, Hospital for Sick Children, Toronto, Ontario

CCFC Student Prize

- Variants in innate immune IBD susceptibility genes are associated with anti-microbial antibodies in Crohn's disease (Abstract 33)
 - T Murdoch¹, J Stempak¹, W Xu², M Silverberg¹
¹Department of Medicine, University of Toronto, Toronto, Ontario; ²Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario
- The adoptive transfer of susceptibility to colitis by macrophages from mice with depression-like behavior (Abstract 34)
 - J Ghia, B Patricia, W Khan, C Stephen
Farncombe Family Digestive Health Research Institute, Hamilton, Ontario
- Changes in the gut intestinal microflora influence behavior in mice (Abstract 35)
 - M Gareau¹, E Wine¹, D Rodrigues¹, M Whary², G MacQueen³, P Sherman¹
¹Hospital for Sick Children, University of Toronto, Toronto, Ontario; ²Massachusetts Institute of Technology, Boston, Massachusetts; ³University of Calgary, Calgary, Alberta
- Interleukin-1 receptor phosphorylation activates Rho kinase to disrupt human gastric tight junctional claudin-4 during *Helicobacter pylori* infection (Abstract 36)
 - T Lapointe¹, P O'Connor¹, N Jones², D Menard³, A Buret¹
¹Biological Sciences & Inflammation Research Network, University of Calgary, Calgary, Alberta; ²Hospital for Sick Children, Toronto, Ontario; ³Department of Anatomy and Cellular Biology, Université de Sherbrooke, Sherbrooke, Québec

11h00-11h40

*SMALL GROUP SESSIONS (See pages 27-32)

Gastroparesis

British Columbia

Celiac Disease in the Pediatric Patient

Quebec

Chronic Diarrhea in Children

Algonquin

MONDAY MARCH 1

	Polypectomy Techniques to Avoid Complications and Recurrence (Sponsored by Olympus)	Manitoba
	Microscopic Colitis and Non-IBD Inflammatory Disorders (Sponsored by Pentax)	Alberta
	Pouchitis	Saskatchewan
	Sessile Serrated Adenomas: Pathology, Epidemiology and Natural History	Nova Scotia
	Transient Elastography: Promises and Pitfalls	New Brunswick
	Non-HCC Liver Tumours in Children	Salon A
	Management of Hepatic Encephalopathy: Lactulose and Beyond	Toronto
	*Please note that pre-registration (online or on-site) is required to gain admittance to Small Group Sessions	
11h40-11h50	Break	
11h50-12h30	*SMALL GROUP SESSIONS (See pages 27-32)	
	Proton Pump Inhibitors (PPIs) and Long Term Complications: Fact or Fallacy?	British Columbia
	Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics	Quebec
	Chronic Diarrhea – Difficult Diagnostic Cases	Algonquin
	Constipation in the Elderly	Manitoba
	Sigmoidoscopy or Colonoscopy? (Sponsored by Pentax)	Alberta
	Enteral and Parental Nutrition for the General Gastroenterologist	Saskatchewan
	Common GI Problems in Immunosuppressed Patients	Nova Scotia
	Relapsing Pyogenic Cholangiopathy	New Brunswick
	Benign Liver Masses (FNH & Hepatic Adenoma) (Sponsored by Gilead)	Salon A
	Familial Cholestasis Syndromes	Toronto
	*Please note that pre-registration (online or on-site) is required to gain admittance to Small Group Sessions	
12h30-13h15	Exhibits and Lunch	Canadian Room & Foyers
13h15-14h45	CASL SYMPOSIUM Update in HBV	Ontario
<hr/>		
Learning Objectives:		
At the end of this session, participants will:		
1. Understand the role of liver biopsy and non-invasive tests of liver fibrosis in the management of chronic hepatitis B.		
2. Appreciate the various endpoints for HBV therapy and understand how they should be used to guide clinical practice.		
3. Recognize antiviral resistance in HBV and institute appropriate salvage therapy.		
<hr/>		
Co-Chairs: Jordan Feld, University of Toronto and Scott Fung, University of Toronto		
<ul style="list-style-type: none"> • Endpoints of Therapy in HBV: Do Clinical Trials Apply to Clinical Practice? – Edward Lin, Scarborough Centenary Hospital • Is Combination Therapy the Answer to Antiviral Resistance in HBV? – Jean-Pierre Villeneuve, Université de Montréal • DEBATE: <i>'Do we need liver biopsy for HBV in 2010?'</i> Pro: David Wong, University of Toronto Con: Mark Levstik, University of Western Ontario • Question and Answer 		

MONDAY MARCH 1

13h15-14h45	<p>CAG BASIC PAPER SESSION: Epithelial Injury and Repair Confederation 5 and 6</p> <p>Co-Chairs: Mélanie Gareau, University of Toronto and Wallace MacNaughton, University of Calgary</p> <p>CCFC Student Prize</p> <ul style="list-style-type: none">• Loss of Smad5 disrupts the intestinal epithelial barrier by disassembling the apical junctional complex and increasing susceptibility to experimental colitis (Abstract 37)<ul style="list-style-type: none">– <u>J Allaire</u>, M Darsigny, S Marcoux, J Schmouth, B Auclair, Y Benoit, F Boudreau, N Perreault <i>Université de Sherbrooke, Sherbrooke, Québec</i>• Src kinases participate in interferon gamma-induced intestinal barrier permeability through regulation of PI3K (Abstract 38)<ul style="list-style-type: none">– <u>D Smyth</u>, V Phan, A Wang, D McKay <i>University of Calgary, Calgary, Alberta</i>• GATA4 as a major intestinal transcriptional regulator of the secretory lectin-related RegIIIβ; (Abstract 39)<ul style="list-style-type: none">– <u>J Bruneau</u>, A Rémillard, G Brouillard, C Asselin, F Boudreau <i>Université de Sherbrooke, Sherbrooke, Québec</i>• Deletion of NLRP3, a gene associated with Crohn's disease, renders mice more susceptible to intestinal inflammation and is associated with alterations in colonic cytokines, inflammatory cell populations and beta-defensin expression (Abstract 40)<ul style="list-style-type: none">– <u>S Hirota</u>¹, J Ng¹, K Parhar¹, Y Li¹, J Tschopp², D Muruve¹, J MacDonald¹, P Beck¹ <i>¹University of Calgary, Calgary, Alberta; ²University of Lausanne, Dorigny, Switzerland</i>• P2Y₂ receptor plays a key role in intestinal epithelial restitution (Abstract 41)<ul style="list-style-type: none">– <u>E Degagné</u>, F Gendron <i>Université de Sherbrooke, Sherbrooke, Québec</i>• Epidermal growth factor receptor transactivation is required for PAR₂-induced COX-2 expression in Caco-2 cells (Abstract 42)<ul style="list-style-type: none">– <u>C Hirota</u>, F Moreau, W MacNaughton <i>University of Calgary, Calgary, Alberta</i>
13h15-14h45	<p>CAG/CASL LIVE ENDOSCOPY 1 Concert Hall</p> <p>Endoscopy in the Pancreas and Biliary Tree</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session, participants will be able to:</p> <ol style="list-style-type: none">1. Appreciate the role of endoscopic ultrasound in the diagnosis and management of pancreatic disorders.2. Better understand the indications and limitations of endoscopic retrograde cholangiopancreatography (ERCP) for management of biliary stone disease.3. Understand the role of endoscopic stenting for palliation of malignant biliary obstruction. <hr/> <p>Faculty: Alan Barkun†, McGill University; Robert Bailey, University of Alberta; Rob Enns, University of British Columbia; Greg Habert†, Lennox Hill Hospital, New York; Paul Kortan†, University of Toronto; Jonathan Love, University of Calgary; Norm Marcon, University of Toronto; Gary May, University of Toronto; Joe Romagnuolo†, Medical University of South Carolina</p> <p>Cases will concentrate on the role of ERCP and endoscopic ultrasound in the diagnosis and treatment of pancreatic-biliary disorders.</p> <p style="text-align: center;">– Sponsored by Olympus –</p>
14h45-15h15	<p>Nutrition Break Canadian Room & Foyers</p>

MONDAY MARCH 1

15h15-16h45	CASL SYMPOSIUM 'Omics' in Liver Disease – From Bench to Bedside	Confederation 5 and 6
<hr/>		
Learning Objectives: At the end of this session, participants will be able to:		
<ol style="list-style-type: none">1. Appreciate how genome-wide scans may be used to evaluate genes that contribute to the development of PBC.2. Understand the role of microarray technology in dissecting innate immune pathways disrupted in patients with hepatitis C virus infection.3. Describe how metabolomic studies of small molecules can help define the complex pathophysiology of hepatic disease.		
<hr/>		
Co-Chairs: Julia Rempel, University of Manitoba and Claudia Zwingmann, Université de Montréal		
<ul style="list-style-type: none">• What Can Genome Wide Scans Tell Us about PBC and Other Autoimmune Diseases? – Katherine Siminovitch, University of Toronto• Question and Answer• Microarray Studies and Liver Disease – Ian McGilvray, University of Toronto• Question and Answer• Metabolomics and Liver Disease – Claudia Zwingmann• Question and Answer		
15h15-16h45	CAG SYMPOSIUM Biomarkers in Gastrointestinal Malignancies	Ontario
<hr/>		
Learning Objectives: At the end of this session, participants will understand the role of biomarkers in:		
<ul style="list-style-type: none">• Predicting the progression of Barrett's esophagus to cancer.• Diagnosis and treatment of pancreatic tumours.• Management of and prognosis related to colon cancer.		
<hr/>		
Co-Chairs: Richard Hunt†, McMaster University and Des Leddin, Dalhousie University		
<ul style="list-style-type: none">• Biomarkers and their Role in Gastroenterology Practice – Des Leddin• Esophagus: Predicting Barrett's Progression to Cancer – Laurette Geldenhuys, Dalhousie University• Pancreas: Diagnosis and Recurrence of Pancreatic Tumours – Malcolm Moore, University of Toronto• Colon: Biomarkers in the Treatment, Recurrence Detection and Prognosis of Colon Cancer – Scott Berry, University of Toronto• Panel Discussion/Question and Answer		
15h05-16h45	CAG/CASL LIVE ENDOSCOPY 2 Treating Dysplasia from the Esophagus to the Colon	Concert Hall
<hr/>		
Learning Objectives: At the end of this session, participants will be able to:		
<ol style="list-style-type: none">1. Understand to role and limitations of digital chromoendoscopy for evaluation of mucosal dysplasia.2. Appreciate the role of endoscopic mucosal resection for staging and treatment of mucosal dysplasia in Barrett's esophagus.3. Review techniques for endoscopic management of large colonic polyps.		
<hr/>		
Faculty: Alan Barkun†, McGill University; Robert Bailey, University of Alberta; Rob Enns, University of British Columbia; Greg Habert†, Lennox Hill Hospital, New York; Paul Kortan†, University of Toronto; Jonathan Love, University of Calgary; Norm Marcon, University of Toronto; Gary May, University of Toronto; Joe Romagnuolo†, Medical University of South Carolina		
Cases will concentrate on the management of mucosal dysplasia in the luminal GI tract.		

MONDAY MARCH 1

16h45-18h15	<p>POSTER SESSION 2</p> <p>Join authors and colleagues and participate in relaxed and informative sessions while enjoying beverages and light snacks. Please be sure to visit the Posters of Distinction located throughout the Exhibit Hall (Canadian Room) and Foyers.</p> <p>– Sponsored by AstraZeneca –</p>	Ballroom & Salon B
18h15-19h30	<p>2010 CDDW/CASL WINTER MEETING AWARDS CEREMONY</p> <p>We invite you to join us at the annual Awards Ceremony to congratulate and celebrate with the many awardees this year. All awards from the CAG, CASL, CDHF and CLF inclusive of research and education, will be formally presented to each awardee.</p>	Ontario
19h30-22h00	<p>GALA EVENT</p> <p>Variety is the Spice of Life!</p> <p>This year's Gala offers an exciting evening that features diverse cultural entertainment, a great meal and of course, fun. Unique entertainers spice up the event and a variety of interactive surprises are sure to please and create fond memories. Join us for an enjoyable evening where the focus is on terrific cuisine, a convivial atmosphere and a sparkling roster of performance artists!</p>	Imperial Room

08h30-10h30

CAG/CASL SYMPOSIUM
Recent Key Papers for Clinicians

Concert Hall

Learning Objectives:

At the end of this session, participants will:

1. Appreciate the importance of using a wire-guided cannulation technique at ERCP, and better understand meta-analysis and assess its methodological value and clinical relevance.
 2. Critically evaluate the current status of serological testing for IBS.
 3. Understand the clinical implications of genetic polymorphisms in the IL28B locus with respect to treatment response in patients with hepatitis C.
 4. Become acquainted with new data regarding the treatment of patients with chronic hepatitis B.
 5. Understand the evidence leading to the FDA advisory on PPI-clopidogrel interactions.
 6. Understand translation of a clinical question to a planned experiment, the clinical relevance of a statistically significant difference, and the selection of papers for publication by scientific journals.
 7. Identify the controversies surrounding the use of ursodeoxycholic acid in PSC.
 8. Understand the limitations of the MELD allocation system for allocation of liver allografts and the potential utility of revisions to this score, including the addition of serum sodium.
-

Co-Chairs: Stephen Somerton, Brantford and David Wong, University of Toronto

*In this first two-hour segment speakers will give a 15-minute concise synopsis of the eight selected papers, summarizing their significance and impact on clinical practice.***Papers:**

- Cennamo V et al. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2009;104(9):2343-50.
– Alan Barkun†, McGill University
- Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. *Aliment Pharmacol Ther* 2009;29:834-42.
– Eamonn Quigley†, University College Cork
- Ge D et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399-401.
– Winnie Wong, University of Alberta
- Marcellin P et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 2008;359(23):2442-55.
– Jordan Feld, University of Toronto
- Laine L, Hennekens, C. Proton pump inhibitor and clopidogrel interaction: Fact or fiction? *Am J Gastroenterol* advance online publication, November 10, 2009.
– Paul Moayyedi†, McMaster University
- Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. *Gastroenterology* 2009;137(1):80-7.
– Richard Hunt†, McMaster University
- Lindor KD et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology* 2009;50(3):808-14.
– Alex Aspinall, University of Calgary
- Kim WR et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. *N Engl J Med* 2008;359(10):1018-26.
– Kelly Burak, University of Calgary

10h30-11h00

Nutrition Break

Concert Hall Foyer

TUESDAY MARCH 2

11h00-11h50	<p>Recent Key Papers for Clinicians</p> <p><i>For this second segment the audience will divide into two groups – one luminal and one liver – for a 50 minute highly interactive session related to two of the luminal and two of the liver papers presented in the symposium.</i></p> <p>Luminal Breakout Session Salon B</p> <p>Facilitator: Stephen Somerton Panel: Alan Barkun†, Eamonn Quigley†</p> <p>Liver Breakout Session Toronto</p> <p>Facilitator: David Wong Panel: Jordan Feld, Winnie Wong</p>
11h50-12h00	Break
12h00-12h50	<p>Recent Key Papers for Clinicians</p> <p><i>For the third segment the audience will again divide into luminal and liver groups for a 50 minute interactive session related to the other two luminal and liver papers presented in the symposium.</i></p> <p>Luminal Breakout Session Salon B</p> <p>Facilitator: Stephen Somerton Panel: Paul Moayyedi†, Richard Hunt†</p> <p>Liver Breakout Session Toronto</p> <p>Facilitator: David Wong Panel: Alex Aspinall, Kelly Burak</p>



American Society for Gastrointestinal Endoscopy (ASGE) Learning Centers

At the ASGE Learning Center, located in the Canadian Room, delegates can rotate at their own pace through three video stations which demonstrate endoscopic techniques and technologies. All nine videos are from the ASGE Endoscopic Learning Library collection.

SATURDAY FEBRUARY 27

Station 1 – Colonoscopy Technique: Basic and Advanced

Douglas K Rex, MD

Total run time: 82 minutes

Station 2 – Biliary Access Techniques for ERCP: From Basic to Advanced

Martin L Freeman MD; Kapil Gupta, MD

Total run time: 63 minutes

Station 3 – Diagnosis and Treatment of Early Gastric Cancer

Hisanao Hamanaka, MD; Takuji Gotoda, MD; Ronald Yeh, MD; Roy Soetikno, MD

Total run time: 27 minutes

– Saturday afternoon ASGE Learning Centre sponsored by Ferring –

SUNDAY FEBRUARY 28

Station 1 – Training for Endosonography (CDROM)

Richard A Erickson, MD; Kenneth J Chang, MD

Station 2 – Endoscopy in the Bariatric Patient

Christopher C Thompson, MD

Total run time: 150 minutes

Station 3 – Endoscopic Looping Techniques

Roy M Soetikno, MD; Jennifer Barro, MD; Shai Friedland, MD

Total run time: 23 minutes

– Sunday ASGE Learning Centre sponsored by Ferring –

MONDAY MARCH 1

Station 1 – Endoscopic Submucosal Dissection for Gastric Superficial Tumors

Joo Young Cho, MD; In Seop Jung, MD; Chang Beom Ryu, MD; Chan Sup Shim, MD

Total run time: 20 minutes

Station 2 – Endoscopic Approach to Hemorrhoids

Rome Jutabha, MD; Tonya Kaltenbach, MD; Roy Soetikno, MD

Total run time: 28 minutes

Station 3 – Endoscopic Management of Periampullary Adenomas

Christopher J Gostout, MD; Douglas Adler, MD

Total run time: 31 minutes

The CAG is grateful to the ASGE for this learning opportunity

Please visit <http://www.asge.org/> to order videos

Participants may claim Section 4 Personal Learning Project credits as defined by
the Royal College of Physicians and Surgeons of Canada

Small Group Sessions

Small group sessions (limit of 35 attendees) are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday session of the same name. For room locations see pages 28-32. Pre-registration required.

LUMINAL TOPICS	Sunday 28 th		Monday 1 st	
	11h00	11h50	11h00	11h50
Non-cardiac Chest Pain		◆		
Difficult Esophageal Stricture <i>Sponsored by Pentax</i>	◆			
Treatment of Eosinophilic Esophagitis across the Age Spectrum	◆			
PPIs and Long Term Complications: Fact or Fallacy?				◆
Gastroparesis			◆	
Celiac Disease in the Pediatric Patient			◆	
Enteral and Parenteral Nutrition for the General Gastroenterologist				◆
Enteral Stenting		◆		
Autoimmune Biliary and Pancreatic Diseases	◆			
Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics		◆		◆
IBD Treatments and the Elderly	◆			
Pouchitis			◆	
Microscopic Colitis and Non-IBD Inflammatory Disorders <i>Sponsored by Pentax</i>			◆	
Quality Assurance and Patient-centered Endoscopy Services in the Era of Limited Resources <i>Sponsored by Pentax</i>		◆		
Capsule/Balloon-assisted Enteroscopy/CT Enteroclysis – Diagnostic Usage	◆			
Polypectomy Techniques to Avoid Complications and Recurrence <i>Monday session sponsored by Olympus</i>	◆		◆	
Sessile Serrated Adenomas: Pathology, Epidemiology and Natural History			◆	
Sigmoidoscopy or Colonoscopy? <i>Sponsored by Pentax</i>				◆
New Advances in Colorectal Cancer Treatment <i>Sponsored by Olympus</i>		◆		
Chronic Diarrhea in Children			◆	
Chronic Diarrhea – Difficult Diagnostic Cases				◆
Constipation in the Elderly				◆
Common Gastrointestinal Problems in Immunosuppressed Patients				◆
Mechanisms Underlying Probiotic Actions in the GI Tract	◆			
Patch Clamping for the Non-patch Clamper		◆		
Statistics Primer		◆		
LIVER TOPICS				
The Many Uses of TIPS	◆			
Pediatric NAFLD	◆			
Management of Non-Esophageal Varices		◆		
Relapsing Pyogenic Cholangiopathy				◆
Transient Elastography: Promises and Pitfalls <i>Supported in part by KNS</i>			◆	
Portal Hypertension in Pregnancy		◆		
Non-HCC Liver Tumours in Children			◆	
Management of Hepatic Encephalopathy: Lactulose and Beyond			◆	
Benign Liver Masses (FNH and Hepatic Adenoma) <i>Sponsored by Gilead</i>				◆
Management of HCC <i>Sponsored by Gilead</i>	◆			
Familial Cholestasis Syndromes				◆
Cystic Diseases of the Liver		◆		

Small Group Sessions

Small group sessions are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday one of the same name. Pre-registration required.

LUMINAL TOPICS

- **Non-cardiac Chest Pain** Sunday, February 28, 11h50 (British Columbia)
Learning Objectives: Understand: 1) The etiological factors leading to non-cardiac chest pain, 2) The investigations appropriate to the diagnosis of non-cardiac chest pain, and 3) The treatment options available for the management of non-cardiac chest pain.
Speaker: David Armstrong†, McMaster University
- **Difficult Esophageal Stricture** Sunday, February 28, 11h00 (Algonquin)
Learning Objectives: 1) Understand risk factors leading to the development of difficult esophageal strictures, 2) Understand the role of bouginage and balloon dilation for the management of these strictures, and 3) Be aware of new techniques such as endoscopic stricturoplasty and stenting for very difficult strictures.
Speaker: Gary May, University of Toronto
Sponsored by Pentax
- **Treatment of Eosinophilic Esophagitis across the Age Spectrum** Sunday, February 28, 11h00 (Quebec)
Learning Objectives: 1) Have an approach to diagnosis and management of eosinophilic esophagitis, and 2) Understand differences between treatment of adults and pediatric age patients.
Speakers: Paul Beck, University of Calgary and Peggy Marcon, University of Toronto
- **PPIs and Long Term Complications: Fact or Fallacy?** Monday, March 1, 11h50 (British Columbia)
Learning Objectives: 1) Understand how to interpret evidence for risk and benefit, and 2) Discuss this in terms of risks of PPI on: A) clopidogrel interaction, B) hip fracture, C) *C. difficile* and D) pneumonia.
Speaker: Paul Moayyedi†, McMaster University
- **Gastroparesis** Monday, March 1, 11h00 (British Columbia)
Learning Objectives: 1) Review the etiology, symptoms, clinical spectrum and severity of gastroparesis, 2) Describe current diagnostic procedures in gastroparesis, and 3) Discuss treatment options and management of patients with gastroparesis.
Speaker: Premysl Bercik, McMaster University
- **Celiac Disease in the Pediatric Patient** Monday, March 1, 11h00 (Quebec)
Learning Objectives: 1) Take an informed position for the advocacy of screening through understanding the prevalence of celiac disease by geographic location and in at-risk groups, 2) Have insight into the state-of the art genetics of celiac disease in the pediatric and adult populations, 3) Address questions pertaining to the quality of life of celiac patients both due to the disease and the gluten-free diet, and 4) Have up to date resources for gluten-free products and patient support.
Speaker: Martha Dirks, Université de Montréal
- **Enteral and Parenteral Nutrition for the General Gastroenterologist** Monday, March 1, 11h50 (Saskatchewan)
Learning Objective: Discuss the nutritional management of acute pancreatitis including principles of early nutrition support, enteral vs. parenteral nutrition, complications of nutrition support and obtaining enteral access.
Speakers: Johane Allard, University of Toronto and Don Duerksen, University of Manitoba
- **Enteral Stenting** Sunday, February 28, 11h50 (Alberta)
Learning Objectives: 1) Discuss the approach to patients with luminal strictures, and 2) Discuss the management of malignant obstruction of the GI tract.
Speaker: Kevin Waschke, McGill University
- **Autoimmune Biliary and Pancreatic Diseases** Sunday, February 28, 11h00 (Saskatchewan)
Learning Objectives: 1) Appreciate the clinical spectrum of autoimmune biliary and pancreatic diseases, 2) Understand which investigations have utility in diagnosing patients and, 3) Evaluate the potential treatments available to patients.
Speakers: Paul Kortant†, University of Toronto and Gideon Hirschfield, University of Toronto

Small Group Sessions Continued

Small group sessions are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday one of the same name. Pre-registration required.

LUMINAL TOPICS Continued

- **Long Term Safety of IBD Therapies in Children and Adults: Steroids vs. Imuran vs. Biologics** Sunday & Monday, February 28 & March 1, 11h50 (Quebec)
Learning Objectives: 1) To be familiar with the frequency and severity of long-term side effects of corticosteroids, immunosuppressives and biologics that are currently indicated for treatment of IBD in children and adults, and 2) To identify algorithms or strategies that minimize the risk of serious adverse events with these drugs for individual patients.
Speakers: Anne Griffiths, University of Toronto and Jan Irvine, University of Toronto
- **IBD Treatments and the Elderly** Sunday, February 28, 11h00 (British Columbia)
Learning Objectives: 1) Identify the effect of aging on IBD pathogenesis and expression, 2) Compare and contrast IBD treatment effects in the elderly compared to the non-elderly, and 3) Identify IBD-therapy associated adverse events unique to the elderly.
Speaker: Richard Fedorak, University of Alberta
- **Pouchitis** Monday, March 1, 11h00 (Saskatchewan)
Learning Objectives: 1) Evaluate types of clinical and endoscopic presentations of pouchitis, and 2) Initiate appropriate management strategies for pouchitis.
Speakers: Gordon Greenberg, University of Toronto and Flavio Habal, University of Toronto
- **Microscopic Colitis and Non-IBD Inflammatory Disorders** Monday, March 1, 11h00 (Alberta)
Learning Objectives: 1) Understand the pathogenesis, epidemiology and risk factors, and develop an approach to diagnosing and treating microscopic colitis, 2) Appreciate the epidemiology and conditions associated with eosinophilic enteritis, and have a strategy for patient diagnosis and management, and 3) Review autoimmune diseases affecting the gut and how to manage these patients.
Speaker: Paul Beck, University of Calgary Sponsored by Pentax
- **Quality Assurance and Patient-centered Endoscopy Services in the Era of Limited Resources** Sunday, February 28, 11h50 (Algonquin)
Learning Objectives: 1) Understand the benefits gained by patients, physicians and services through quality assurance in endoscopy, 2) Gain knowledge about what is required to get started with quality assurance in endoscopy, and 3) Become familiar with currently available programs that facilitate quality assurance for endoscopy, namely the Endoscopy Global Rating Scale and CAG's Quality Endoscopy Program.
Speakers: Catherine Dubé, University of Calgary and Donald MacIntosh, Dalhousie University Sponsored by Pentax
- **Capsule/Balloon-assisted Enteroscopy/CT Enteroclysis – Diagnostic Usage** Sunday, February 28, 11h00 (Alberta)
Learning Objectives: 1) Develop a general understanding of these technologies for the diagnosis of small bowel disorders, 2) Review the advantages and disadvantages of these technologies, and 3) Review which patients to perform these tests on and when to order them.
Speaker: Steve Heitman, University of Calgary
- **Polypectomy Techniques to Avoid Complications and Recurrence** Sunday & Monday, February 28 & March 1, 11h00 (Manitoba)
Learning Objectives: 1) Understand that the definition of a difficult polyp is related to its location and size, and the skill of the endoscopist, 2) Know the role of injection solution therapy, snares, coagulation forceps, clips, and scopes, 3) Understand how to manage complications, and 4) Recognize when to stop and consider surgical therapy.
Speaker: Norm Marcon, University of Toronto Monday session sponsored by Olympus
- **Sessile Serrated Adenomas: Pathology, Epidemiology and Natural History** Monday, March 1, 11h00 (Nova Scotia)
Learning Objectives: Understand: 1) the clinical importance of serrated lesions and their relationship to right colon carcinomas, 2) the terminology and histology of serrated lesions in general, with particular attention on sessile serrated adenomas, 3) the molecular basis of serrated lesions and the proposed mechanism(s) by which they progress to malignancy, and 4) the clinical implications and therapeutic options for patients after a diagnosis of a serrated polyp.
Speakers: Robert Hilsden, University of Calgary and Catherine Streutker, University of Toronto

Small Group Sessions Continued

Small group sessions are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday one of the same name. Pre-registration required.

LUMINAL TOPICS Continued

- **Sigmoidoscopy or Colonoscopy?** Monday, March 1, 11h50 (Alberta)
Learning Objectives: 1) Be familiar with the issues around the debate on cancer prevention vs. early detection strategies, 2) Understand the technical and human resource differences between the two prevention strategies, and 3) Be knowledgeable of the anticipated impact of a flexible sigmoidoscopy strategy.
Speakers: Nancy Baxter, University of Toronto and Des Leddin, Dalhousie University
Sponsored by Pentax
- **Endoscopic vs. Surgical Management of Large or Malignant Polyps** Sunday, February 28, 11h50 (Manitoba)
Learning Objectives: 1) Understand new endoscopic modalities and devices for large colon polyps, 2) Know the new Kyoto classifications and the new Japanese histological guidelines for risk of non-surgical therapy, 3) Know how to manage complications, 4) Understand the outcomes of Minimal Access colorectal surgery, and 5) Appreciate the role of endoscopy in preparing for colorectal surgery for polyps.
Speakers: Margherita Cadeddu, McMaster University and Norm Marcon, University of Toronto
Sponsored by Olympus
- **Chronic Diarrhea in Children** Monday, March 1, 11h00 (Algonquin)
Learning Objectives: 1) Identify the leading causes of chronic diarrhea in childhood, 2) Discuss recent insights into the pathogenesis of chronic diarrhea, and 3) Develop a practical management approach for these cases.
Speakers: Robert Issenman, McMaster University and Eytan Wine, University of Alberta
- **Chronic Diarrhea – Difficult Diagnostic Cases** Monday, March 1, 11h50 (Algonquin)
Learning Objective: Outline an effective approach to the investigation and management of chronic diarrhea.
Speaker: Trevor Seatont, McMaster University
- **Constipation in the Elderly** Monday, March 1, 11h50 (Manitoba)
Learning Objectives: 1) Understand mechanisms of constipation in general and specifically in the elderly patient, and 2) Review the approach to and management of constipation in this patient population.
Speaker: Christopher Andrews, University of Calgary
- **Common Gastrointestinal Problems in Immunosuppressed Patients** Monday, March 1, 11h50 (Nova Scotia)
Learning Objectives: 1) Review the GI toxicities of the immunosuppressive medications, 2) Understand the gastrointestinal manifestation of cytomegalovirus infection and other opportunistic infections, and 3) Outline an approach to diarrhea in a solid organ transplant recipient.
Speaker: Kelly Burak, University of Calgary
- **Mechanisms Underlying Probiotic Actions in the GI Tract** Sunday, February 28, 11h00 (Nova Scotia)
Learning Objectives: 1) Know the definitions of probiotic, prebiotic, and synbiotics, 2) Recognize current levels of evidence supporting the use of probiotics in various GI disorders, and 3) Understand how probiotics may alter gut function in GI health and disease.
Speakers: Karen Madsen, University of Alberta and Elaine Petrof, Queen's University
- **Patch Clamping for the Non-patch Clamper** Sunday, February 28, 11h50 (Nova Scotia)
Learning Objectives: 1) Understand the principles of voltage and current clamp, 2) Identify what useful information can be gleaned by using this approach, and 3) Identify the weaknesses and limitations of this technique.
Speaker: Alan Lomax, Queen's University
- **Statistics Primer** Sunday, February 28, 11h50 (Saskatchewan)
Learning Objectives: Understand: 1) the difference between t-tests and chi-square tests and their use in randomized controlled trials; and 2) the rationale underlying the use of multivariate statistics and their use in observational studies.
Speakers: Maida Sewitch, McGill University and Jill Tinmouth, University of Toronto

Small Group Sessions Continued

Small group sessions are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday one of the same name. Pre-registration required.

LIVER TOPICS

- **The Many Uses of TIPS** Sunday, February 28, 11h00 (New Brunswick)
Learning Objectives: To learn about: 1) the indications for TIPS insertion, 2) patient selection for TIPS insertion, and 3) follow-up after TIPS insertion.
Speaker: Florence Wong, University of Toronto

- **Pediatric NAFLD** Sunday, February 28, 11h00 (Salon A)
Learning Objectives: To become familiar with: 1) emerging trends in the global prevalence of NAFLD in childhood, and 2) emerging treatment strategies focused (including lifestyle modification) in childhood NAFLD.
Speaker: Diana Mager, University of Alberta

- **Management of Non-Esophageal Varices** Sunday, February 28, 11h50 (New Brunswick)
Learning Objectives: 1) Understand the role of the gastroenterologist in the treatment of gastric varices, 2) Review the non-endoscopic therapies for treating gastric varices, and 3) Provide an overview of the management of ectopic varices.
Speaker: Steve Heitman, University of Calgary

- **Relapsing Pyogenic Cholangiopathy** Monday, March 1, 11h50 (New Brunswick)
Learning Objectives: 1) Identify the clinical features of patients with relapsing pyogenic cholangiopathy, and 2) Describe the diagnosis approach and treatment of relapsing pyogenic cholangiopathy.
Speaker: Aldo Montano-Loza, University of Alberta

- **Transient Elastography: Promises and Pitfalls** Monday, March 1, 11h00 (New Brunswick)
Learning Objectives: 1) Describe the principles underlying transient elastography for staging liver fibrosis, 2) Describe the utility of transient elastography for predicting fibrosis in various hepatic conditions, and 3) Understand potential limitations of using transient elastography for the staging of liver fibrosis in clinical practice.
Speakers: Magdy Elkashab, University of Toronto and Rob Myers, University of Calgary

- **Portal Hypertension in Pregnancy** Sunday, February 28, 11h50 (Salon A)
Learning Objectives: 1) Understand the physiologic changes in pregnancy and how it impacts on underlying portal hypertension, and 2) Become more comfortable with the management of portal hypertension throughout pregnancy.
Speaker: Jennifer Leonard, Memorial University

- **Non-HCC Liver Tumours in Children** Monday, March 1, 11h00 (Salon A)
Learning Objectives: 1) Describe the epidemiology of the most common benign and malignant liver tumours in children, 2) Understand the role of diagnostic imaging in differentiating pediatric liver masses, and 3) Assess the need for interventional radiology, medical therapy, resection or liver transplantation.
Speaker: Steve Martin, University of Calgary

- **Management of Hepatic Encephalopathy: Lactulose and Beyond** Monday, March 1, 11h00 (Toronto)
Learning Objectives: 1) Understand the role of ammonia and other substances in the development of encephalopathy, 2) See how lactulose is viewed in the world of evidence-based medicine, and 3) Consider using other treatments for encephalopathy in their daily practice.
Speakers: Dean Karvellas, University of Alberta and Phil Wong, McGill University

Small Group Sessions Continued

Small group sessions are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Monday sessions are a repeat of the Sunday one of the same name. Pre-registration required.

LIVER TOPICS Continued

- **Benign Liver Masses (FNH and Hepatic Adenoma)** Monday, March 1, 11h50 (Salon A)
Learning Objective: Identify new and existing imaging modalities to help discriminate between benign liver masses.
Speaker: Alex Aspinall, University of Calgary Sponsored by Gilead

- **Management of HCC** Sunday, February 28, 11h00 (Toronto)
Learning Objectives: 1) Understand the epidemiology of HCC, and 2) Know advantages and limitations of the major therapeutic options for HCC.
Speakers: Paul Greig, University of Toronto and Eberhard Renner, University of Toronto Sponsored by Gilead

- **Familial Cholestasis Syndromes** Monday, March 1, 11h50 (Toronto)
Learning Objectives: 1) Describe the epidemiology of the most common benign and malignant liver tumours in children, 2) Understand the role of diagnostic imaging in differentiating pediatric liver masses, and 3) Assess the need for interventional radiology, medical therapy, resection or liver transplantation.
Speaker: Eve Roberts, University of Toronto

- **Cystic Diseases of the Liver** Sunday, February 28, 11h50 (Toronto)
Learning Objectives: 1) To review investigation and clinical management of cystic diseases of the liver and biliary tree using case discussions, and 2) To encourage discussion of participants cases from their own practices.
Speaker: Vince Bain, University of Alberta

**CDDW/CASL WINTER MEETING
FUTURE VENUES**

2011 Vancouver, February 22 – March 4

2012 Montréal, February 21-29

SUMMARY OF ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA SECTION 1 CREDITS

<u>Saturday, February 27</u>	<u>Credits</u>	<u>Session Title</u>
08h30-10h30	2	CAG/CPAC/CASL Postgraduate Course: Debating the Hot Issues in Colorectal Cancer Screening – Part 1
11h00-12h30	1.5	CAG/CPAC/CASL Postgraduate Course: Debating the Hot Issues in Colorectal Cancer Screening – Part 2
11h00-12h30	1.5	CASL Basic Paper Session
13h15-14h45	1.5	CAG Clinical Paper Session
13h15-14h45	1.5	CAG/CASL Postgraduate Course: The Liver and Other Organs
15h15-17h15	2	CAG/CASL Postgraduate Course: Metabolic Liver Disease
15h15-17h15	2	CAG Symposium: New Insights into Neurogastroenterology
18h30-19h30	1	McKenna Lecture
<u>Sunday, February 28</u>		
08h00-09h00	1	CAG Breakfast with the Experts: Difficult Cases in IBD
08h00-09h00	1	CASL Breakfast with the Experts: Cholestatic Liver Diseases – An Update
08h00-09h00	1	CAG Breakfast with the Experts: Celiac Disease Challenges
08h30-10h30	2	CAG Symposium: Danger Signaling and Host Defense; NODs, TLRs, NLRPs and More!
09h00-09h45	0.75	CLF-CASL Sass Kortsak Lecture
09h45-10h30	0.75	CLF-CASL Gold Medal Lecture
11h00-12h30	1.5	Workshop for Trainees: Dispatches from the Front Lines of the Research World
11h00-11h40	0.75	Small Group Sessions
11h50-12h30	0.75	Small Group Sessions
13h15-14h45	1.5	CAG Basic Paper Session
13h15-14h45	1.5	CASL Clinical Paper Session
13h15-14h45	1.5	CAG Symposium: Advances in IBD Diagnosis and Therapeutics
18h00-21h00	1	Evening Event: Pancreatitis – Dealing with Anti-Coagulants
18h00-21h00	1	Evening Event: The Future of Hepatitis C Therapy – Peginterferon, Ribavirin, and Beyond
18h00-21h00	1	Evening Event: Screening Colonoscopy – How Do We Make a Difference?
18h00-21h00	1	Evening Event: Research in Canada: Strategic Directions from Funding Partners CCFC, CDHF, CIHR, CLF
<u>Monday, March 1</u>		
08h00-09h00	1	CAG Breakfast with the Experts: Difficult Cases in IBD
08h00-09h00	1	CASL Breakfast with the Experts: Approach to Liver Masses
08h00-09h00	1	CAG Breakfast with the Experts: Management of Upper GI Bleeding: What Do the New Guidelines Tell Us?
09h00-10h30	1.5	CASL Symposium: Liver Transplantation
09h00-09h30	0.5	Young Investigator Lecture
09h30-10h00	0.5	Research Excellence Lecture
10h00-10h30	0.5	Education Excellence Lecture
11h00-12h30	1.5	CASL Basic Paper Session
11h00-12h30	1.5	CAG Basic Paper Session
11h00-11h40	0.75	Small Group Sessions
11h50-12h30	0.75	Small Group Sessions
13h15-14h45	1.5	CASL Symposium: Update in HBV
13h15-14h45	1.5	CAG Basic Paper Session
13h15-14h45	1.5	Live Endoscopy 1 – Endoscopy in the Pancreas and Biliary Tree
15h15-16h45	1.5	Live Endoscopy 2 – Treating Dysplasia from the Esophagus to the Colon
15h15-16h45	1.5	CASL Symposium: 'Omics' in Liver Disease: From Bench to Bedside
15h15-16h45	1.5	CAG Symposium: Biomarkers in GI Malignancies
<u>Tuesday, March 2</u>		
08h30-10h30	2	CAG/CASL Symposium: Recent Key Papers for Clinicians
11h00-11h50	1	Luminal Breakout Session
11h00-11h50	1	Liver Breakout Session
12h00-12h50	1	Luminal Breakout Session
12h00-12h50	1	Liver Breakout Session

This educational program offers a total of 81 hours of Section 1 accredited learning and up to 25.5 credits per delegate
Please visit <http://www.cag-acg.org/education/accreditation/certificates.aspx> to evaluate the conference and print your certificate

EXHIBITORS

Company: **Abbott Laboratories**
 Address: 8401 Trans Canada Highway
 Saint-Laurent, QC H4S 1Z1
 Telephone: 514-832-7220
 Fax: 514-832-7837
 Contact: Sylvie St-Pierre/Josée Bernier
 Booth Number: 1006

Abbott is committed to delivering breakthrough products that make a significant impact on medical practice, on the quality of care and on the lives of the people who need them. Humira is the only self-injectable biologic treatment for moderately to severely active Crohn's disease.

Company: **Advanced Surgi-Pharm Inc.**
 Address: 850 Halpern Avenue
 Montreal, QC H9P 1G6
 Telephone: 800-661-5432/514.631.7988
 Fax: 514.631.9083
 Contact: Janice Geronimo
 Booth Number: 903

ADVANCED SURGI-PHARM INC. was established in 1992 as a specialty distributor of value-added surgical products Targeting the orthopedic, neuro, gynecological and central sterile dept. of the hospital markets in Canada. The specialty products largely encompass instrumentation and equipment. Advanced Surgi-Pharm Inc. has developed into an industry leader in Canada for several of the lines that they represent in on behalf of U.S., International and domestic manufacturers.

Company: **ALPCO Diagnostics**
 Address: 26 Keewaydin Drive, Unit G
 Salem, NH 03079
 Telephone: 800-592-5726
 Fax: 603-898-6854
 Contact: Daniel Keefe
 Booth Number: 909

ALPCO is committed to providing the highest quality immunoassays for research and clinical use while maintaining our unrivaled position as a leader in bringing unique and esoteric products to the field. Our product line features over 1000 immunoassays encompassing many disciplines, including *Cytokine Research, Endocrinology, Diabetes & Obesity, and Neurology*. Coupling this menu with singular customer service and expert technical support, ALPCO truly offers *Immunoassays Beyond the Ordinary*.

Company: **AMT Endoscopy**
 Address: 20 Steckle Place, Unit #16
 Kitchener, ON N2E 2C3
 Telephone: 888-803-6799
 Fax: 519-895-2299
 Contact: Amanda Habermehl
 Booth Number: 108

AMT Endoscopy is a provider of niche and clinically advanced GI Endoscopy products. Our team of GI product specialists remains dedicated to introducing advanced applications and solutions into the ever growing field of Gastroenterology. With the launch of products like i-Snare and Platinum Roth Nets we continue to thrive in the Endoscopy market. How do YOU treat Barrett's esophagus? We have a solution, come by our booth and see it!

Company: **AstraZeneca Canada Inc.**
 Address: 1004 Middlegate Road
 Mississauga, ON L4Y 1M4
 Telephone: 800-565-5877
 Fax: 905-277-2060
 Contact: Shelley Hillman
 Booth Number: 401

AstraZeneca is a leading global pharmaceutical company with an extensive product portfolio spanning six major therapeutic areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology, and respiratory. AstraZeneca's Canadian headquarters is located in Mississauga, Ontario, with a state-of-the-art drug discovery centre based in Montreal, Quebec. For more information, visit the company's website at www.astrazeneca.ca.

Company: **Axcan Pharma Inc.**
 Address: 597 Laurier Boulevard
 Mont-Saint-Hilaire, QC J3H 6C4
 Telephone: 800-565-3255/450-467-5138
 Fax: 450-464-9979
 Contact: Bruce McTavish (ext. 4002)
 Fred Wieler (ext. 5562)
 Booth Number: 301

Axcan is a privately-held, leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease (Salofalk®, Cortenema®), irritable bowel syndrome (Modulon®), cholestatic liver diseases (URSO DS®) and complications related to pancreatic insufficiency (Ultrase®, Viokase®). Axcan's products are marketed by its own specialized sales forces in North America and the European Union and through commercial collaborations in many markets around the world.

EXHIBITORS

Company: Beutlich® Pharmaceuticals
Address: 1541 Shields Drive
 Waukegan, IL 60085
Telephone: 800-238-8542
Fax: 847-473-1122
Contact: Jim Delaney
Booth Number: 917

Beutlich Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of innovative OTC solutions for pain management and patient care. Providing quality healthcare products since 1954, Beutlich is best known for its HurriCaine® brand of topical anesthetics. HurriCaine® Spray, indicated for temporary gag-reflex suppression during upper endoscopies, has a fast onset of 20 seconds and a short duration of 15 minutes which allows patients to eat and drink immediately following their procedure, reducing recovery time. **FEATURED PRODUCTS:** NEW CEO-TWO® Laxative Suppositories –CO2-releasing suppository that works within 30 minutes without cramping or discomfort, 2) HurriCaine® Magic Mouth Rinse recipes for stomatitis and mucositis. www.beutlich.com.

Company: Bio-K+ International Inc.
Address: Scientific Park, 495 Boul. Armand-Frappier
 Laval, QC. H7V 4B3
Telephone: 800-593-2465/450-978-2465
Fax: 450-978-9729
Contact: Shanti Hallard
Booth Number: 712

Bio-K+ International Inc. is a family business and a research-based manufacturer specializing in clinically proven probiotic. The Bio-K+ CL1285® line of products is manufactured from an exclusive patented formula of L. acidophilus CL1285 and L. casei LBC80R. Clinical trials have shown that it promotes and maintains good health and balance within the digestive system. It is fast-acting in the body which can best be explained by the elevated amount of live bacteria upon consumption (between 30 and 50 billion, depending on the product); the bio activity is conserved until they reach their final destination, your intestine. For more information visit the company's website at www.biokplus.com.

Company: Boston Scientific Ltd.
Address: 5060 Spectrum Way, Suite 500
 Mississauga, ON L4W 5N5
Telephone: 905-696-1800
Fax: 905-696-1893
Contact: Annie St-Cyr
Booth Number: 208

Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less invasive medical devices and procedures. The company's products and technologies are designed to reduce risk, trauma, cost, procedure time and the need for aftercare.

Company: Bristol-Myers Squibb Canada Co.
Address: 2344, Alfred-Nobel, Suite 300
 Montréal, QC H4S 0A4
Telephone: 514-333-4208
Contact: Marie-Josée St-Pierre
Booth Number: 508

Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS & Hepatitis-B), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montréal, Québec.

Company: Canadian Association of Gastroenterology
Address: 1540 Cornwall Road, Suite 224
 Oakville, ON L6J 7W5
Telephone: 888-780-0007
Fax: 905-829-0242
Contact: Paul Sinclair
Booth Location: 2

Over 1100 members including gastroenterologists, surgeons, pediatricians, radiologists and basic scientists comprise the CAG. CAG members are actively involved in research, education and patient care in all areas of digestive health and disease, contributing to the economic and social health of all Canadians.

Company: Canadian Digestive Health Foundation
Address: 2511 Scotch Pine Drive
 Oakville, ON L6M 4C3
Telephone: 905-829-3949
Fax: 905-829-3949
Contact: Richard Fedorak/Catherine Mulvale
Booth Location: 805

The Canadian Digestive Health Foundation believes it is unnecessary and unacceptable for over 20 million Canadians to suffer from digestive disorders. As the Foundation of the Canadian Association of Gastroenterology (CAG), we work with leading physicians, scientists, and health care professionals to help Canadians understand and take control of their digestive health with confidence and optimism. Through education and research, we empower Canadians to: **REDUCE** the incidence and prevalence of digestive disorders; **IMPROVE** the understanding of digestive health issues; **SUPPORT** those who suffer from digestive disorders; **ENHANCE** quality of life for those living with digestive disorders.

EXHIBITORS

Company: Canadian Liver Foundation
 Address: 2235 Sheppard Avenue East, Suite 1500
 Toronto, ON M2J 5B5
 Telephone: 800-563-5483
 Fax: 416-491-4952
 Contact: Gary Fagan
 Booth Location: 807

The Canadian Liver Foundation (CLF) is a national charity committed to promoting liver health and reducing the incidence and impact of all forms of liver disease by supporting education and research into causes, diagnoses, prevention and treatment. The CLF has contributed millions of dollars to liver research and education in Canada. Through its LIVERight campaign, the Canadian Liver Foundation wants to make liver health a priority for each and every Canadian – including individuals, health care professionals, government and industry. LIVERight. Learn How. Visit LIVER.ca.

Company: Cangene Corporation
 Address: 155 Innovation Drive
 Winnipeg, MB R3T 5Y3
 Telephone: 1-877-CANGENE or 204-275-4200
 Fax: 204-269-7003
 Contact: David Young
 Booth Location: 103

Cangene is a fully integrated biopharmaceutical company with drug development and manufacturing expertise that allows for focused efforts to make therapeutics for infectious diseases. Cangene's increasing revenues allow the Company to expand its pipeline of biodefence and infectious-disease products. The majority of products are hyperimmunes — specialized antibody products that may aid in the fight against medical challenges such as hepatitis B, smallpox, botulism and anthrax. The Company's flagship infectious disease product, HepaGam B®, is the first intravenous hepatitis B immune globulin (HBIG) approved by both Health Canada and the FDA. For more information about Cangene visit our website at www.cangene.com.

Company: Carsen Medical Inc.
 Address: 14-151 Amber Street
 Markham, ON L3R 3B3
 Telephone: 866-677-4121
 Fax: 866-677-4122
 Contact: David Murphy
 Booth Number: 104

A trusted partner in Canadian Healthcare, Carsen Medical Inc. is an independent Canadian-owned company dedicated to innovative technology supporting Endoscopy and Infection Control in ambulatory care, the operating room and CSR/SPD departments. With support and client service staff in every province and territory, and exclusive distribution of leading-edge products such as: Fujinon Inc., DBE Double Balloon Endoscopy® and 500 Series High Definition Endoscopy™ Systems, MiroCam® Capsule Endoscopy Systems and Medivator Automated Endoscope Reprocessors, Carsen Medical is uniquely positioned to assist Canadian Gastroenterology professionals to deliver the best in patient care.

Company: CEDARLANE®
 Address: 4410 Paletta
 Burlington, ON L7L 5R2
 Telephone: 289-288-0001
 Fax: 289-288-0020
 Contact: Eddie Johnson/Sana Jawed
 Booth Number: 919

CEDARLANE® (www.cedarlanelabs.com) (ISO 9001, ISO 13485) is a 100% Canadian owned company, specializing in providing high quality research and diagnostic reagents to the life science community. We offer one of the most extensive product listings in the world both domestically and internationally (>1000 suppliers in Canada; >100 suppliers in the US) allowing our customers the opportunity to 'Consolidate & Save'. Cedarlane Diagnostics, (www.cedarlanedx.com) a division of Cedarlane, provides our clinical customers with licensed diagnostic products including GastroPanel®-A first-line diagnostic test for dyspeptic patients.

Company: Cook Medical
 Address: 111 Sandiford Drive
 Stouffville, ON L4A 7X5
 Telephone: 905-640-7110/800-668-0300
 Fax: 905-640-6804
 Contact: Lee Ann Staley
 Booth Number: 100

Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures. Today, the company integrates device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of gastroenterology; aortic intervention; interventional cardiology; critical care medicine; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. www.cookmedical.com.

Company: Crohn's and Colitis Foundation
 Address: 60 St. Clair Avenue East, Suite 600
 Toronto, ON M4T 1N5
 Telephone: 416-920-5035 ext. 219
 Fax: 416-929-0364
 Contact: Rea Ganesh
 Booth Location: 803

The Crohn's and Colitis Foundation of Canada (CCFC) is a not-for-profit medical research foundation dedicated to finding the cure for IBD. CCFC has more than 65,000 supporters and includes members in approximately 80 local volunteer groups across Canada. To date, CCFC has invested over \$61 million in major medical research projects and is one of the world's leading sources of non-governmental funding of IBD research. Education is a very important part of our mandate. We provide information to patients, their families, health professionals and the public through our education brochures, speakers' events and our member publications.

EXHIBITORS

Company: Danone/Activia
Address: 100 rue de Lauzon
Boucherville, QC J4B 1E6
Telephone: 450-655-7331
Fax: 450-655-9034
Contact: Jessica Wright
Booth Number: 613

Activia from Danone is a probiotic yogurt that contains the unique and exclusive probiotic strain B.L Regularis™ DN-173 010, which is scientifically proven to improve slow transit time. For more information visit: www.activia.ca and www.danactive.ca

Company: Ethicon Endo-Surgery Inc. - Sedasys Systems
Address: 200 Whitehall Drive
Markham, Ontario L3R 0T5
Telephone: 800-268-5577
Contact: Brad Nickle
Booth Number: 804

Ethicon Endo-Surgery, Inc. (EES), develops and markets advanced medical devices for minimally invasive and open surgical procedures. We focus on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. The SEDASYS® System, developed by Ethicon-Endo-Surgery, Inc (EES), is a computer-assisted personalized sedation system. It is designed for use by healthcare professional teams to assist in the sedation of ASA Class I and ASA Class II patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy). The System monitors and records patient vital signs, including oxygen saturation, respiratory rate, heart rate, blood pressure, end-tidal carbon dioxide and patient responsiveness. For information, visit www.ijmp.ca.

Company: Ferring Pharmaceuticals
Address: 200 Yorkland Boulevard, Suite 800
North York, ON M2J 5C1
Telephone: 416-490-0121
Fax: 416-493-1692
Contact: Dan Cloutier
Booth Number: 609

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and the important field of gastroenterology. New this year at our booth is: 1) Pentasa's latest advancements in patient adherence, 2) A leading edge Canadian study with Pico-Salax, 3) Recent clinical data on our probiotics VSL#3 and TuZen. Ferring is happy to provide gastroenterologists with teaching aids, brochures and other educational materials related to all of our products for your fellows, residents and patients.

Company: Gilead Sciences Canada Inc.
Address: 6711 Mississauga Road, Suite 202
Mississauga, ON L5N 2W3
Telephone: 866-565-5409
Fax: 866-809-0406
Contact: Paul Drolet
Booth Number: 101

Gilead Sciences applies the best of biopharmaceutical science to create innovative medicines that advance patient care. Our research and development programs focus on small molecule therapeutics for the potential treatment of HIV, hepatitis and pulmonary arterial hypertension. Gilead also has an active research program in inhaled therapeutics for the treatment of cystic fibrosis-related lung infections.

Company: Given Imaging
Address: 3950 Shackleford Road, Suite 500
Duluth, GA 30096
Telephone: 800-448-3644
Fax: 770-810-1731
Contact: Jeanne Cook
Booth Number: 923

Given Imaging, Ltd. is the leader in developing capsules-based GI diagnostic toll. Given is engage in the development, manufacture, and marketing of diagnostic products for the visualization and Ph monitoring for detection of disorders of the gastrointestinal tract. Its principal products are Pillcam SB, Pillcam ESO, Pillcam Colon, Agile patency capsule and Bravo Ph monitoring system. It has operations in the United States, Canada, Latin America, Europe, the Middle East, Africa, Asia, Australia, and Japan. The company was founded in 1998 and is headquartered in Yoqneam, Israel.

Company: Hoffmann-La Roche Limited
Address: 2455 Meadowpine Boulevard
Mississauga, ON L5N 6L7
Telephone: 905-542-5558
Fax: 905-542-5803
Contact: Fiona McCloskey
Booth Number: 901

Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system.

EXHIBITORS

Company: **Instrumed Surgical**
Address: 2180 Dunwin Drive, Unit 5 & 6
Mississauga, ON L5L 5M8
Telephone: 905-820-0902
Fax: 905-820-0983
Contacts: Karen Ineson/Len Ineson/Shannon Janula
Booth Number: 705

Instrumed Surgical has been servicing the G.I. Community since 1987. At this year's meeting we are especially pleased to introduce our new line of stents. The Niti-S Stents are manufactured by Taewoong Medical and are sold worldwide. In addition to our new line of stents, we are also introducing the New Polar Wand from G.I. Supply. The same company that brings you the very popular "Spot" permanent tattoo for marking the colon. We will also be promoting the Viaduct, an innovative and unique stent, as well as many other products. We look forward to meeting you and discussing these exciting new devices.

Company: **Inter Medico**
Address: 50 Valleywood Drive, Unit 1
Markham, Ontario L3R 6E9
Telephone: 800-387-9643/905-470-2520 Ext. 202
Fax: 905-470-2381
Contact: Brad Bloom
Booth Number: 911

Inter Medico is a Canadian distributor that specializes in providing leading edge instrumentation and reagent solutions to clinical and research laboratories. We are uniquely positioned to offer products from our key partner in the area of autoimmunity, INOVA Diagnostics. Their single focus allows them to offer you unmatched quality, reliable consistency, and excellent value on the most comprehensive range of autoimmune testing reagents available anywhere. This includes screening and detection kits for Celiac Disease, Inflammatory Bowel Disease and Liver Disease.

Company: **Isomass Scientific Inc.**
Address: #140, 5700-1st Street S.W.
Calgary, AB T2H 3A9
Telephone: 800-363-7823 / 403-255-6631
Fax: 403-255-6958
Contact: Nik Binder
Booth Number: 209

Isomass Scientific Inc. is the Authorized Canadian Agent for Thermo Scientific Isotope Ratio Mass Spectrometers and Wagner Analysen Technik GmbH Iris-3 Infra Red Isotope Analyzers. The Iris-3 is a non-radioactive diagnostic tool capable of analyzing ¹³C-breath samples for H. Pylori infection, measurement of gastric emptying, quantitative liver function tests, exocrine pancreatic function and orocecal transit time using Lactose ¹³C-ureide to diagnose SIBO. This non-invasive test can safely be used without radiation hazard for all patients, including children and pregnant women.

Company: **KNS Canada Inc.**
Address: 210 Silver Star Boulevard, Suite 805
Toronto ON M1V 5J9
Telephone: 800-233-1008, 416-644-0231, 416-642-1425
Fax: 416-644 0232
Contact: Shahid H Khandker
Booth Number: 109

FibroScan[®], world's only non-invasive fibrosis diagnostic device can accurately diagnose various grades of liver fibrosis in minutes. With S, M and XL probe, FibroScan[®] has paediatric, adult and obese applications. FibroScan[®] is an excellent fibrosis screening tool. FibroScan[®] is also a valuable tool to monitor post cirrhotic complications. Evalico[®], is a liver support filter used in chronic, acute and AOCLF. Evaflox[®] used with Interferon and combination drugs can dramatically reduce viral load and achieve high SVR in Genotype 1. These two products not licensed for sale by Health Canada. For more information please contact 1-800-233-1008 or visit www.knscanada.com or booth #109.

Company: **Merck & Co., Inc.**
Address: 16750 Trans Canada Highway
Kirkland, QC H9H 4M7
Telephone: 800-361-2353
Fax: 514-695-8040
Contact: Sarah Minielly/Richard Plourde
Booth Numbers: 1010 (Merck) & 907 (Schering-Plough Canada Consumer HealthCare)

Today's Merck* is one of Canada's leading healthcare companies. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit www.merck.com. Please visit us at the Merck booth for information about Remicade (infliximab) and Pegatron (peginterferon alfa-2b + ribavirin), and at the RestoraLAX booth for information about RestoraLAX (Polyethylene Glycol 3350). Merck Gastroenterology and Virology: proud to partner with Canadian gastroenterologists to improve the lives of patients suffering from IBD and hepatitis C. *Merck Frosst Canada Ltd. and Schering-Plough Canada Inc. are now operating together as Merck.

EXHIBITORS

Company: Mui Scientific
Address: 145 Traders Boulevard East, Unit 34
Mississauga, ON L4Z 3L3
Telephone: 905-890-5525
Fax: 905-890-3523
Contact: Claudia Scali
Booth Number: 202

Mui Scientific is a leading manufacturer of water-perfused infusion pumps and catheters for motility studies. In 2004, we acquired Dentsleeve International Ltd. in Australia and relocated its manufacturing plant to Mississauga, doubling our product line. Aside from our extensive array of standard products, we also specialize in the design and manufacture of customized reusable and single-use multi-lumen PVC and silicone catheters and barostat catheters. We are also the Exclusive Canadian Distributor for Sierra Scientific Instruments' high-resolution and high-definition motility systems and accessories; pH/Impedance monitoring systems and accessories; and, as of 2009, Alpine Biomed's full line of gastro-diagnostic products.

Company: Novartis Pharmaceuticals Canada Inc.
Address: 385 Bouchard Boulevard
Dorval, QC H9S 1A9
Telephone: 514-633-7880 Ext. 3296
Contact: Tara Carlin
Booth Number: 308

Novartis is a world leader in the discovery, development, manufacturing and marketing of medicines. The Novartis commitment to liver disease focuses on meeting the needs of viral hepatitis patients, developing a portfolio of compounds with complementary mechanisms of action and supporting patients undergoing liver transplantation.

Company: Nycomed Canada Inc.
Address: 435 North Service Road West, 1st Floor
Oakville, ON L6M 4X8
Telephone: 905-469-9333/888-367-3331
Contact: Shino Phillips
Booth Number: 501

Nycomed Canada Inc. is the Canadian subsidiary of Nycomed; a privately owned research-based pharmaceutical company. Nycomed is based in Oakville, Ontario, with more than 140 employees across the country. Through its innovative products and dedicated people, Nycomed is committed to improving the health of Canadians by providing brand name, science-based medicines that matter.

Company: Odan Laboratories Ltd.
Address: 325 Stillview
Pointe-Claire, QC H9R 2Y6
Telephone: 514-428-1628
Fax: 514-428-9783
Contact: Howard Kaminsky
Booth Number: 913

Odan Laboratories Ltd., a privately held 100% Canadian pharmaceutical company, brings more than 35 years of experience in developing and manufacturing branded pharmaceutical specialties and generic health care products. Over the years, we developed an extensive expertise in Gastroenterology treatments and made it one of our major Health Specialties. Our more recent release is Purg-Odan™, an easy to take purgative indicated to prepare patients before colonoscopy, colon x-ray, or surgical procedures. Odan is renowned for providing quality medicines at affordable prices to consumers, while addressing the professional needs of the pharmacist, physician and health professionals. Odan products are distributed to retail pharmacies, hospitals, government institutions, and pharmaceutical wholesalers.

Company: Olympus Canada Inc.
Address: 151 Telson Road
Markham, ON L3R 1E7
Telephone: 905-969-3062
Fax: 905-479-2595
Contact: Laura Tasso
Booth Number: 1016

Olympus is a precision technology leader, creating innovative opto-digital solutions. Olympus Canada's mission is to serve the Canadian healthcare customers with integrated product solutions, supported by educational, consulting services and financial solutions that help our customers achieve exceptional results. At CDDW, Olympus is exhibiting world's first and only endoscope platform featuring high-definition television (HDTV) and Narrow Band Imaging (NBI), a broadened EndoTherapy product line, the EnteroPro small bowel solution, and the Aloka ProSound SSD-Alpha10 processor to the Endoscopic Ultrasound line up.

Company: Pentax Canada Inc.
Address: 1770 Argentia Road
Mississauga, ON L5N 3S7
Telephone: 800-750-5558
Fax: 905-286-5571
Contact: Jason Taylor
Booth Number: 201

DISCOVER PENTAX DEDICATION. Our focus and dedication to flexible endoscopy allows us to deliver world-class products, people and service, enabling our customers to provide the best possible care for their patients.

EXHIBITORS

Company: Pfizer Canada Inc.
 Address: 17300 Trans Canada Highway
 Kirkland, BC H9J 2M5
 Telephone: 800-267-2553
 Contact: Nancy Di Matteo
 Booth Number: 309

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc invests more than US\$7 billion annually in R&D to discover and develop innovative life-saving and life-enhancing medicines in a wide range of therapeutic areas, including arthritis, cardiovascular disease, endocrinology, HIV/AIDS, infectious disease, neurological disease, oncology, ophthalmology and smoking cessation.

Company: Shire Canada Inc.
 Address: 2250 Alfred-Nobel, Suite 500
 Saint-Laurent, QC H4S 2C9
 Telephone: 514-787-2339
 Fax: 514-787-2428
 Contact: Dominique Gauthier
 Booth Number: 409

Shire Canada Inc. is a wholly owned subsidiary of Shire plc, a global specialty biopharmaceutical company that works closely with specialist physicians to develop and market medicines that improve the quality of life for patients, their families and caregivers. Shire focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies and gastrointestinal diseases. Shire Canada's operations are headquartered in Montréal, Québec. For further information on Shire, please visit the Company's website: www.shire.com.

Company: Pulsus Group Inc.
 Address: 2902 South Sheridan Way
 Oakville, ON L6J 7L6
 Telephone: 905-829-4770
 Fax: 905-829-4799
 Contact: Ann LeBlanc
 Booth Number: 809

Pulsus Group is a Canadian publishing company specializing in high quality, peer review medical journals including *The Canadian Journal of Gastroenterology*. These publications have all been adopted as official publications of their respective medical societies. They are distributed and read around the world and are indexed in the established medical literature services. Pulsus Group also publishes official supplements to its prestigious journals and produces custom publications. For more information please visit our website at www.pulsus.com.

Company: Somagen Diagnostics
 Address: 9220-25 Avenue
 Edmonton, AB T6N 1E1
 Telephone: 780-702-9500
 Fax: 780-438-6595
 Contact: Anton Ehret
 Booth Numbers: 905

Somagen Diagnostics has been a leader in Canadian diagnostic medicine for over 20 years. Somagen offers specialised innovative technologies and solutions for our clinical laboratories through our distribution partnerships with prominent diagnostic suppliers. Our partners include Meridian Bioscience and their distinct enteric pathogen assays such as H. pylori stool antigen (HpSA), Polymedco with walk-away automated immunochemical solutions for fecal occult blood testing (FOBT) used for colon cancer screening and Phadia, a world leader in celiac disease screening with Celikey® human recombinant tissue transglutaminase IgA and food allergen testing with ImmunoCAP® technology. For more information: www.Somagen.com.

Company: Robarts Clinical Trials
 Address: 100 Perth Drive
 London, ON N6A 5K8
 Telephone: 519 931-5216
 Fax: 519 931-5284
 Contact: Fern Livingstone
 Booth Number: 915

Robarts Clinical Trials is a full service CRO with extensive experience in the design and conduct of clinical studies across a broad range of therapeutic areas. Robarts offers expert consultation, a wide variety of study management services, a comprehensive safety surveillance program, as well as a range of customized support for our sponsors and investigators. We have the experience to manage the central processing of video images and to provide specialized training. Our Central Image Management Service can facilitate timely and consistent evaluation of trial endpoints for global studies. For more information visit our website at www.robartscclinicaltrials.ca.

Company: Takeda Canada Inc.
 Address: 2700 Matheson Blvd. East, #300W
 Mississauga, ON L4W 4V9
 Telephone: 905-206-0165
 Contact: Laurene Redding
 Booth Number: 509

Takeda Canada Inc. is dedicated to providing innovative products that improve the lives of patients. Based in Mississauga, Ontario, Takeda Canada is a part of the Takeda Pharmaceutical Company Limited family, the largest pharmaceutical company in Japan. Takeda Canada, founded April 1, 2009, currently markets ACTOS® (pioglitazone HCl) for the treatment of type 2 diabetes. Through Takeda Global Research & Development Center, Inc., Millennium – The Takeda Oncology Company and business alliances, the company has a robust pipeline with compounds in development for metabolic and cardiovascular diseases, oncology, gastroenterology, urology, gynaecology, CNS, bone & joint diseases and others www.takedacanada.com.

EXHIBITORS

Company: UCB Pharma Canada Inc.
Address: 4145 North Service Road, Suite 200
Burlington, ON L7L 6A3
Telephone: 905-315-5065
Fax: 905-315-5066
Contact: Craig Campbell
Booth Number: 709

UCB Pharma Canada is the Canadian subsidiary of UCB, a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. Headquartered in Brussels (Belgium), UCB (www.ucb-group.com) employs more than 12,000 people in over 40 countries. UCB Pharma Canada was officially incorporated in November 2006, with the objective of bringing a next-generation, convenient therapy to the Canadian market for auto-immune, inflammatory diseases. Truly a patient-focused organization, UCB Pharma Canada is focused on bringing new and innovative programs to patients, and the specialists who treat them, to help improve the lives of people living with severe diseases.

Company: Warner Chilcott Canada
Address: 4711 Yonge Street, 12th Floor
Toronto, ON M2N 6K8
Telephone: 416-716-6409
Fax: 866-292-7975
Contact: Samuel Lee
Booth Number: 408

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology, and urology segments of the Canadian, U.S., and Western European pharmaceuticals markets. With the recent acquisition of P&G Pharmaceuticals, Warner Chilcott has a strong portfolio of trusted, quality, leadership brands that includes Asacol® 800 (mesalamine delayed release tablets) and builds on a heritage of supporting the Canadian GI community for over 20 years.

CAHN EDUCATION DAY
Friday, February 26, 2010
Fairmont Royal York Hotel, Toronto, Ontario

AGENDA

07:00 - 07:50	BREAKFAST BUFFET & REGISTRATION
07:50 - 08:00	WELCOME <i>Cheryl Dale, MScN, RN (EC) NP – Adult - President, CAHN</i>
08:00 - 10:30	Session #1 - <i>Moderator – Michelle Crosby</i>
08:00 - 08:45	Chronic Hepatitis C -2010 & Beyond <i>Jordan Feld, MD, MPH, FRCP (C)</i>
08:45 - 09:30	Dermatological Complications of Chronic Hepatitis C Disease & Treatment <i>Jaggi Rao, MD, FRCP(C)</i>
09:30 - 10:30	Esophageal Varices: Treatment and Implications <i>Maria Laryea, MD , FRCP(C)</i>
10:30 - 10:45	NUTRITIONAL BREAK
10:45 - 12:15	Session #2 - <i>Moderator – Kathy Dallaire</i>
10:45 - 11:30	Hepatitis B Treatment Beyond Lamivudine <i>Lorne Tyrrell, MD, FRCP (C)</i>
11:30 - 12:15	Nursing Management of End Stage Hepatocellular Carcinoma <i>Heidi Penstone, RN, OCN Case Manager</i>
12:15 - 13:00	LUNCH
13:00 - 13:45	Session # 3 - Breakout Sessions
#1	Post-transplant treatment of Chronic Hepatitis C <i>Moderator -Michelle Crosby</i> <i>Mark Levstik, MD, FRCP (C)</i>
#2	Nutritional Requirements of Cirrhotic and Chronic Hepatitis Patients <i>Moderator -</i> <i>Lynne Sinclair, HBSc, RD, Clinical Dietician</i>
#3	Interpretation and Implications of Lab Results Pre, During & Post Treatment <i>Moderator – Geri Hirsch</i> <i>Yvonne Lynch Hill, RN, MN Clinical Nurse Specialist</i>
13:45 – 15:15	Session #4 - <i>Moderator – Kathy Poldre</i>
13:45 – 14:25	Psychiatric Assessment and Management of Hepatitis Patients <i>Amy Morrison, RN,RPN</i>
14:25 – 15:15	Counseling the Liver Disease Patient on Sexual Dysfunction and Viral Transmission Risk <i>Giuseppe (Joe) Morelli, MD</i>
15:00 – 15:30	BREAK
15:30 – 15:30	Session #5 - Abstract Presentations - <i>Moderator - Jo-Ann Ford</i>
15:30 – 15:50	#1 –Evaluating Interprofessional Partnerships for Chronic Illness Care in Four BC Communities - <i>Gail Butt, RN PhD</i>
15:50 – 16:10	#2- Health Related Quality of Life in Patients with Chronic Liver Disease including Hepatitis C Viral Infection Attending a Collaborative Practice with Nurse Practitioners and Hepatologist. – <i>Geri Hirsch, MSN RN-NP</i>
16:10 – 16:30	#3 - TBA
Wrap – up	Sharon Bojarski and Stephanie Eiloart

CAG PRESIDENTS

1961-1962	Richard D McKenna (McGill University)	1975-1976	Richard R Gillies (University of Ottawa)	1989-1990	Iain G Cleator (University of British Columbia)
1962-1963	Robert C Dickson (Dalhousie University)	1976-1977	Bernard J Perey (Université de Sherbrooke)	1990-1991	Eldon A Shaffer (University of Calgary)
1963-1964	Walter C Mackenzie (University of Alberta)	1977-1978	Leslie S Valberg (University Western Ontario)	1991-1992	Suzanne E Lemire (Université Laval)
1964-1965	Eric M Nanson (University of Saskatchewan)	1978-1979	Wilfred M Weinstein (University of Alberta)	1992-1993	Richard H Hunt (McMaster University)
1965-1966	Paul Letendre (Université de Montréal)	1979-1980	Florent Thibert (Université de Montréal)	1993-1994	Stephen M Collins (McMaster University)
1966-1967	KJR Wightman (University of Toronto)	1980-1981	Jacques Kessler (McGill University)	1994-1996	D Grant Gall (University of Calgary)
1967-1968	Ivan T Beck (Queen's University)	1981-1982	Gordon G Forstner (University of Toronto)	1996-1997	J Joseph Connon (University of Toronto)
1968-1969	Abraham Bogoch (University of British Columbia)	1982-1983	Cameron Harrison (University of British Columbia)	1997-1998	Gary A Levy (University of Toronto)
1969-1970	Douglas G Kinnear (McGill University)	1983-1984	Laurington R DaCosta (Queen's University)	1998-2000	Richard Fedorak (University of Alberta)
1970-1971	J Alan L Gilbert (University of Alberta)	1984-1985	William C Watson (University of Western Ontario)	2000-2002	John L Wallace (University of Calgary)
1971-1972	John M Finlay (University of Toronto)	1985-1986	Claude C Roy (Université de Montréal)	2002-2004	Philip M Sherman (University of Toronto)
1972-1973	James F Lind (University of Manitoba)	1986-1987	C Noel Williams (Dalhousie University)	2004-2006	Desmond J Leddin (Dalhousie University)
1973-1974	Joseph J Sidorov (Dalhousie University)	1987-1988	Alan BR Thomson (University of Alberta)	2006-2008	William Paterson (Queen's University)
1974-1975	Jacques O Gagnon (Université de Montréal)	1988-1989	Aubrey Groll (Queen's University)	2008-2010	Ronald Bridges (University of Calgary)
				2010-	David Morgan (McMaster University)

THE RICHARD D MCKENNA LECTURERS

1968	Henry L Bockus	1971	Franz J Ingelfinger	1973	Irwin M Arias
1969	Morton I Grossman	1972	Sheila Sherlock	1974	Kurt J Isselbacher
1970	George A Hallenback	1972	Andrew W Kay	1975	William Summerskill

THE RICHARD D MCKENNA MEMORIAL LECTURERS

1976	Henri Sarles	1988	Leslie S Valberg	2000	Charles O Elson
1977	Rene Menguy	1989	Claude C Roy	2001	Juan R Malagelada
1978	Howard M Spiro	1990	John K MacFarlane	2002	Joseph Sung
1979	Alan F Hofmann	1991	Wilfred M Weinstein	2003	Kim Barrett
1980	JJ Bernier	1992	Francisco Vilardell	2004	W. Allan Walker
1981	Ivan T Beck	1993	David Y Graham	2005	Guido Tytgat
1982	Phillip P Toskes	1994	Gilbert A Castro	2006	Peter B Cotton
1983	Henri Bismuth	1995	D Neil Granger	2007	John Dent
1984	Thomas R Hendrix	1996	Leonard R Johnson	2008	Stephen Collins
1985	John M Dietschy	1997	Leslie Turnberg	2009	Daniel Podolsky
1986	Martin C Carey	1998	Sir Roy Calne		
1987	R Hermon Dowling	1999	Eugene B Chang		

CAG DISTINGUISHED SERVICE AWARD WINNERS

1992	Carl A Goresky	1994	Edwin E Daniel	2002	Richard H Hunt
1992	James A Barrowman (posthumously)	1995	Richard R Gillies	2002	Eldon Shaffer
1992	Ivan T Beck	1995	Abraham Bogoch	2003	Micheline Ste-Marie
1993	Doug Kinnear	1995	Florent Thibert	2004	Nicholas Diamant
1993	Gordon Forstner	1995	JAL Gilbert	2004	Norman Marcon
1993	Joseph J Sidorov	1996	Claude C Roy	2006	Aubrey Groll
1993	Joseph J Sidorov	1998	Kursheed N Jeejeebhoy	2007	J Joseph Connon
1994	Louis J Cole	1998	Edward Prokipchuk	2008	Mary Perdue
1994	Jack Finlay	2000	Alan BR Thomson		
1994	Leslie Valberg	2000	C Noel Williams		

CAG EDUCATION EXCELLENCE AWARD LECTURERS

2003	Claude Roy	2005	Khursheed Jeejeebhoy	2007	Alan BR Thomson
2004	Ivan T. Beck	2006	Lloyd Sutherland	2008	Desmond Leddin
				2009	David Armstrong

KOPELMAN AWARD LECTURERS

2003	David Whitcomb	2005	Dana Philpott	2007	Jack Satsangi
				2009	Philip Sherman

CAG RESEARCH EXCELLENCE AWARD LECTURERS

1993	Alan BR Thomson	1999	Philip M Sherman	2005	Kris Chadee
1994	Claude C Roy	2000	William G Paterson	2006	Keith Sharkey
1995	Stephen M Collins	2001	Mary Perdue	2007	André Buret
1996	Kursheed N Jeejeebhoy	2002	Jan Huizinga	2008	Stephen Vanner
1997	Gordon R Greenberg	2003	Daniel Ménard	2009	Derek McKay
1998	John L Wallace	2004	Jonathan Meddings		

CAG VISITING PROFESSOR AWARD WINNERS

1982	Kursheed N Jeejeebhoy	1993	Stephen M Collins	2003	Keith A Sharkey
1983	Claude C Roy	1994	Gary A Levy	2004	Sander van Zanten
1984	Eldon A Shaffer	1995	Gordon G Forstner	2005	Brian Feagan
1985	J Richard Hamilton	1997	D Grant Gall	2006	Gordon R Greenberg
1987	Richard H Hunt	1998	Mary Perdue	2007	John Wallace
1988	Laurence M Blendis	1999	Lloyd Sutherland	2008	Philip Sherman
1990	James A Barrowman	2000	Ernest Seidman	2009	Alan NG Barkun
1991	E Jenny Heathcote	2001	Jonathan Meddings		
1992	C Noel Williams	2002	Richard Fedorak		

CAG YOUNG EDUCATOR AWARD LECTURERS

2005	Janice Barkey	2007	Jamie Gregor	2009	Nicola Jones
2006	John Marshall	2008	Sylvain Coderre		

CAG YOUNG INVESTIGATOR AWARD LECTURERS

1993	Philip M Sherman	1999	Keith A Sharkey	2005	Nicola Jones
1994	John L Wallace	2000	Paul Kubes	2006	Nathalie Rivard
1995	Jonathan B Meddings	2001	Derek M'Kay	2007	Bruce Vallance
1996	Stephen S Vanner	2002	Wallace MacNaughton	2008	John Marshall
1997	Herbert Gaisano	2003	Young-In Kim	2009	John Brumell
1998	Gervais Tougas	2004	Nathalie Vergnolle		

CASL PRESIDENTS

1985-1987	Eldon A Shaffer (University of Calgary)	1992-1994	Pierre-Michel Huet (University of Montréal)	2004-2006	Morris Sherman (University of Toronto)
1987-1988	W Wayne Lutt (University of Manitoba)	1994-1996	E Jenny Heathcote (University of Toronto)	2006-2008	Marc Deschênes (McGill University)
1988-1989	Jerome B Simon (Queen's University)	1996-1998	Eve A Roberts (University of Toronto)	2008-2010	Eric Yoshida (University of British Columbia)
1989-1990	Lloyd Sutherland (University of Calgary)	1998-2000	Samuel Lee (University of Calgary)	2010-	Winnie Wong (University of Alberta)
1990-1991	Laurence M Blendis (University of Toronto)	2000-2002	Paul Adams (University of Western Ontario)		
1991-1992	Gerald Y Minuk (University of Manitoba)	2002-2004	Vincent Bain (University of Alberta)		

CLF/CASL GOLD MEDALISTS

1983	Jean-Pierre Benhamou	1993	Telfer B Reynolds	2003	Roger Butterworth
1984	Robert Purcell	1994	M James Phillips	2004	E Jenny Heathcote
1985	Rudi Schmid	1995	Diane W Cox	2005	Ian R Wanless
1986	Sheila Sherlock	1996	Laurence M Blendis	2006	Harvey Alter
1987	Aron Rappaport	1997	Lawrie W Powell	2007	S Victor Feinman
1988	Carl A Goresky	1998	William Wall	2008	Eve Roberts
1989	Hyman J Zimmerman	1999	Juan Rodes	2009	Jean-Pierre Villeneuve
1990	Baruch S Blumberg	2000	Lorne Tyrell		
1991	Hector Orrego	2001	Jay Hoofnagle		
1992	Roger Williams	2002	Pierre-Michel Huet		

CASL/SASS KORTSAK LECTURESHIP

1990	Irmin Sternlieb	1996	Alex P Mowat (posthumously)	2002	Jean-Bernard Otte
1992	Claude C Roy			2004	Andrée Rasquin
1994	Daniel Alagille	1998	William Balistreri	2006	David H Perlmutter
		2000	Frederick Suchy	2008	Milton Finegold

DR. ABR THOMSON/DR. CN WILLIAMS AWARD

2002	Robin McLeod	2005	Robert Hilsden	2008	Ramy Abaskharoun
2003	John Wojcik	2006	Laura Arbour	2009	Robert Myers
2004	Greg Kichian	2007	Karen Wong		

**2010 CAG RESEARCH PROGRAM
IN COLLABORATION WITH THE CIHR AND OUR VALUED RESEARCH PARTNERS**

CAG / CIHR / CCFC New Investigator Award (1)
(award is for three years)

CAG / CIHR / Olympus Endoscopic Research Operating Grant (1)
(award is for two years)

CAG / CIHR / AstraZeneca Operating Grant (1)
(award is for two years)

CAG / CIHR / Ferring Lower Gastrointestinal Research Operating
Grant (1) (award is for two years)

CAG / CIHR / Abbott IBD Operating Grant (1)
(award is for two years)

CAG / CIHR / CCFC Fellowships (3)
(awards are for two years)

CAG / CIHR / Abbott IBD Fellowships (2)
(awards are for two years)

CAG / CIHR / Axcan Fellowship (1)
(award is for two years)

CAG / CIHR / AstraZeneca Research Initiative Award (1)
(award is for two years)

CAG / CIHR / Pentax Therapeutic Endoscopy Fellowship (1)
(award is for two years)

CAG / CIHR / Ferring IBD Fellowship (1)
(award is for one year)

CAG / Nycomed Research Resident Awards (2)

CAG / Shire Research Resident Award (1)

CAG / Procter & Gamble Research Resident Award (1)

CAG / CIHR Summer Studentships (up to 4)

CCFC / CIHR Summer Studentships (up to 6)

The CAG wishes to express its sincere appreciation to the above sponsors for their support of these
Research Programs.